Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
35 "Kyung Hee Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1-Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial
Dong Ki Lee, Choong-kun Lee, Hyo Song Kim, Sun Jin Sym, Dae Young Zang, Ki Hyang Kim, Joo Han Lim, Hae Su Kim, Kyung Hee Lee, Heon Yung Gee, Sun Young Rha, Hyunki Kim, Minkyu Jung
Received July 25, 2024  Accepted November 9, 2024  Published online November 12, 2024  
DOI: https://doi.org/10.4143/crt.2024.705    [Accepted]
AbstractAbstract PDF
Purpose
The nProfiler 1 Stomach Cancer Assay (nProfiler1), designed to predict responses to fluorouracil-based adjuvant chemotherapy, measures the expression of four gastric cancer target genes (GZMB, WARS, SFRP4, and CDX1). The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS). This study aimed to validate the nProfiler1 assay using a distinct cohort from the POST trial.
Materials and Methods
The nProfiler1 assay stratifies patients into three groups (low-risk, intermediate-risk, and high-risk) using the prognostic single-patient classifier and two groups (chemotherapy-benefit and no-benefit) using the predictive single-patient classifier. The nProfiler1 assay was applied to formalin-fixed paraffin-embedded slides obtained from the POST trial. Disease-free survival (DFS) and overall survival (OS), including 5-year survival rates, were calculated for the enrolled patients.
Results
Of the 153 patients in the POST trial, 118 were included in the post-hoc analysis. With a median follow-up of 57.9 months, no significant difference in DFS or OS was observed between the SP and DS groups. The prognostic single-patient classifier predicted the OS in the SP group (p=0.0425) but not in the DS group (p=0.5940). The chemotherapy-benefit group exhibited numerically longer DFS than the no-benefit group in the SP and DS groups.
Conclusion
The nProfiler1 assay offers valuable insights into the prognosis and efficacy of adjuvant chemotherapy based on fluorouracil plus platinum doublet regimens but not docetaxel-containing regimens. Further validation with larger patient cohorts and different regimens is warranted.
  • 406 View
  • 60 Download
Close layer
General
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim
Cancer Res Treat. 2023;55(4):1096-1103.   Published online April 7, 2023
DOI: https://doi.org/10.4143/crt.2022.1565
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by  
  • Evaluation of self-assembling properties of paclitaxel-biotin conjugates
    Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
    Nano-Structures & Nano-Objects.2024; 40: 101375.     CrossRef
  • 3,557 View
  • 218 Download
  • 1 Crossref
Close layer
Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer
Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, JinShil Kim, Su-Jin Koh
Cancer Res Treat. 2019;51(4):1632-1638.   Published online April 18, 2019
DOI: https://doi.org/10.4143/crt.2019.009
AbstractAbstract PDFPubReaderePub
Purpose
Physician Orders for Life-Sustaining Treatment (POLST) form is a legal document for terminally ill patients to make medical decisions with physicians near the end-of-life. A multicenter prospective study was conducted to evaluate the feasibility of POLST administration in actual oncological practice.
Materials and Methods
Patients with terminal cancer, age ≥ 20 years, and capable of communicating were eligible. The primary endpoint was the completion rate of POLST. Data about physicians’ or patients’ barriers were also collected.
Results
From June to December 2017, 336 patients from seven hospitals were eligible. Median patient age was 66 years (range, 20 to 94 years); 52.7% were male; and 60.4% had poor performance status. Primary cancer sites were hepato-pancreato-biliary (26.2%), lung (23.2%), and gastrointestinal (19.9%). Expected survival duration was 10.6±7.3 weeks, with 41.2% receiving hospice care, 37.9% showing progression after cancer treatment, and the remaining patients were under active treatment (15.8%) or initially diagnosed with terminal cancer (5.1%). POLST forms were introduced to 60.1% of patients, and 31.3% signed the form. Physicians’ barriers were reluctance of family (49.7%), lack of rapport (44.8%), patients’ denial of prognosis (34.3%), lack of time (22.7%), guilty feelings (21.5%), and uncertainty about either prognosis (21.0%) or the right time to discuss POLST (16.6%). The patients’ barriers were the lack of knowledge/understanding of POLST (65.1%), emotional discomfort (63.5%), difficulty in decision-making (66.7%), or denial of prognosis (14.3%).
Conclusion
One-third of patients completed POLST forms, and various barriers were identified. To overcome such barriers, social engagement, education, and systematic support might be necessary.

Citations

Citations to this article as recorded by  
  • Characteristics of Life-Sustaining Treatment Decisions: National Data Analysis in South Korea
    Jiyeon Choi, Heejung Jeon, Ilhak Lee
    Asian Bioethics Review.2024; 16(1): 33.     CrossRef
  • An Integrative Review of the State of POLST Science: What Do We Know and Where Do We Go?
    Elizabeth E. Umberfield, Matthew C. Fields, Rachel Lenko, Teryn P. Morgan, Elissa Schuler Adair, Erik K. Fromme, Hillary D. Lum, Alvin H. Moss, Neil S. Wenger, Rebecca L. Sudore, Susan E. Hickman
    Journal of the American Medical Directors Association.2024; 25(4): 557.     CrossRef
  • Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study
    Hyeon-Su Im, Insook Lee, Shinmi Kim, Jong Soo Lee, Ju-Hee Kim, Jae Young Moon, Byung Kyu Park, Kyung Hee Lee, Myung Ah Lee, Sanghoon Han, Yoonki Hong, Hyeyeoung Kim, Jaekyung Cheon, Su-Jin Koh
    BMC Medical Ethics.2023;[Epub]     CrossRef
  • Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement
    Dae Seog Heo, Shin Hye Yoo, Bhumsuk Keam, Sang Ho Yoo, Younsuck Koh
    The Korean Journal of Hospice and Palliative Care.2022; 25(1): 1.     CrossRef
  • Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer
    Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, Su-Jin Koh
    Supportive Care in Cancer.2022; 30(9): 7431.     CrossRef
  • The Medical Orders for Scope of Treatment (MOST) form completion: a retrospective study
    Anastasia A. Mallidou, Coby Tschanz, Elisabeth Antifeau, Kyoung Young Lee, Jenipher Kayuni Mtambo, Holly Heckl
    BMC Health Services Research.2022;[Epub]     CrossRef
  • Recommended summary plan for emergency care and treatment: ReSPECT a mixed-methods study
    Gavin D Perkins, Claire A Hawkes, Karin Eli, James Griffin, Claire Jacques, Caroline J Huxley, Keith Couper, Cynthia Ochieng, Jonathan Fuld, Zoe Fritz, Rob George, Doug Gould, Richard Lilford, Martin Underwood, Catherine Baldock, Chris Bassford, Peter-Mar
    Health and Social Care Delivery Research.2022; 10(40): 1.     CrossRef
  • Emergency Healthcare Providers’ Knowledge about and Attitudes toward Advance Directives: A Cross-Sectional Study between Nurses and Emergency Medical Technicians at an Emergency Department
    Sun Woo Hong, Shinmi Kim, Yu Jin Yun, Hyun Sook Jung, JaeLan Shim, JinShil Kim
    International Journal of Environmental Research and Public Health.2021; 18(3): 1158.     CrossRef
  • Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
    Shin Hye Yoo, Wonho Choi, Yejin Kim, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2021; 53(2): 584.     CrossRef
  • We Want More Than Life-Sustaining Treatment during End-of-Life Care: Focus-Group Interviews
    Mirinae Kim, Minju Kim
    International Journal of Environmental Research and Public Health.2021; 18(9): 4415.     CrossRef
  • Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act
    Hyeyeong Kim, Hyeon-Su Im, Kyong Og Lee, Young Joo Min, Jae-Cheol Jo, Yunsuk Choi, Yoo Jin Lee, Daseul Kang, Changyoung Kim, Su-Jin Koh, Jaekyung Cheon
    BMC Palliative Care.2021;[Epub]     CrossRef
  • Asian patients’ perspectives on advance care planning: A mixed-method systematic review and conceptual framework
    Diah Martina, Olaf P Geerse, Cheng-Pei Lin, Martina S Kristanti, Wichor M Bramer, Masanori Mori, Ida J Korfage, Agnes van der Heide, Judith AC Rietjens, Carin CD van der Rijt
    Palliative Medicine.2021; 35(10): 1776.     CrossRef
  • Life-Sustaining Treatment States in Korean Cancer Patients after Enforcement of Act on Decisions on Life-Sustaining Treatment for Patients at the End of Life
    Young-Woong Won, Hwa Jung Kim, Jung Hye Kwon, Ha Yeon Lee, Sun Kyung Baek, Yu Jung Kim, Do Yeun Kim, Hyewon Ryu
    Cancer Research and Treatment.2021; 53(4): 908.     CrossRef
  • Advance care planning in Asian culture
    Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng
    Japanese Journal of Clinical Oncology.2020; 50(9): 976.     CrossRef
  • Preference and Performance Fidelity of Modified Korean Physician Order for Life-Sustaining Treatment (MK-POLST) Items in Hospice Patients with Cancer
    Ji Hee Han, Hye Sook Chun, Tae Hee Kim, Rock Bum Kim, Jung Hoon Kim, Jung Hun Kang
    The Korean Journal of Hospice and Palliative Care.2019; 22(4): 198.     CrossRef
  • 8,359 View
  • 164 Download
  • 12 Web of Science
  • 15 Crossref
Close layer
Validity and Reliability of Korean Version of Simplified Nutritional Appetite Questionnaire in Patients with Advanced Cancer: A Multicenter, Longitudinal Study
So Yeon Oh, Su-Jin Koh, Ji Yeon Baek, Kyung A Kwon, Hei-Cheul Jeung, Kyung Hee Lee, Young-Woong Won, Hyun Jung Lee
Cancer Res Treat. 2019;51(4):1612-1619.   Published online April 12, 2019
DOI: https://doi.org/10.4143/crt.2018.505
AbstractAbstract PDFPubReaderePub
Purpose
Malnutrition and a loss of muscle mass are frequent in cancer patients and have a negative effect on clinical outcome. Nutrition risk screening aims to increase awareness and allow early recognition and treatment of cancer cachexia. Therefore, screenings should be brief, inexpensive, highly sensitive, and have good specificity. Simplified Nutritional Appetite Questionnaire (SNAQ) is a simple screening tool including four questions, and validated to predict weight loss within 6 months in community-dwelling adults and nursing home residents. Our study aimed to translate the SNAQ into Korean, and to assess the validity and reliability of the translated screening tool in advanced cancer patients.
Materials and Methods
The SNAQ was translated into Korean according to linguistic validation. The internal consistency of the SNAQ was evaluated by Cronbach’s alpha coefficient. Test-retest reliability was evaluated using the intraclass correlation coefficient. Concurrent validity was evaluated by measuring the Pearson’s correlation coefficient between the SNAQ and Mini-Nutritional Assessment (MNA) and Patient-Generated Subjective Global Assessment (PG-SGA).
Results
In the 194 patients included in full analysis set, cancer stage was predominantly metastatic (98.5%), the mean age was 60 years (range, 23 to 81 years), and the mean body mass index was 24 kg/m2 (range, 15.6 to 39.6 kg/m2). According to MNA score ≤ 11, 57 patients (29.4%) were malnourished. The mean score (±standard deviation) of the Korean version of the SNAQ was 13.8±2.5 with a range of 6-19. Cronbach’s alpha coefficient was 0.737, and intraclass correlation coefficient was 0.869. The SNAQ was moderately correlated with MNA (r=0.404, p < 0.001) and PG-SGA (r=–0.530, p < 0.001). A significant weight loss of > 5% of the original bodyweightwithin 6 months occurred in 46 of the 186 patients (24.7%). SNAQ score ≤ 14 predicted > 5% weight loss with a sensitivity of 56.5% and a specificity of 44.3%.
Conclusion
The Korean version of the SNAQ had high validity and reliability. SNAQ is useful for the screening tool for advanced cancer patients. The SNAQ had a limitation to predict impending weight loss in advanced cancer patients.

Citations

Citations to this article as recorded by  
  • Demographic, clinical and psychological predictors of malnutrition among people with liver cancer
    Yumi Kim, Sung Reul Kim, Kyounghae Kim, Su Jong Yu
    European Journal of Oncology Nursing.2024; 68: 102497.     CrossRef
  • Therapeutic Potential of Combined Herbal Medicine and Electroacupuncture in Mild Cognitive Impairment Through Cytokine Modulation: An Observational Study
    Jung-Hee Jang, Hyeong Joon Jun, ChaYoung Lee, Eunjin Sohn, Ojin Kwon, Dong-Hoon Kang, Muhammad Umar, In Chul Jung, Soo-Jin Jeong
    Neuropsychiatric Disease and Treatment.2024; Volume 20: 1331.     CrossRef
  • Reliability and validity of Chinese version of the Simplified Nutritional Appetite Questionnaire (SNAQ) in community-dwelling old people
    Gaojie Feng, Xiaohong Sun, Qiumei Wang, Fei Lu, Yuanyuan Li, Yaru Zhou, Xiaohong Liu
    Geriatric Nursing.2024; 59: 351.     CrossRef
  • Malnutrition risk screening in adult oncology outpatients: An ASPEN systematic review and clinical recommendations
    Elaine B. Trujillo, Kunal C. Kadakia, Cynthia Thomson, Fang Fang Zhang, Alicia Livinski, Kim Pollard, Todd Mattox, Anne Tucker, Valaree Williams, Declan Walsh, Steven Clinton, Aaron Grossberg, Gordon Jensen, Rhone Levin, Jeannine Mills, Anurag Singh, Mere
    Journal of Parenteral and Enteral Nutrition.2024; 48(8): 874.     CrossRef
  • Assessment of nutritional status using objective and subjective methods in Greek patients with cancer
    Konstantina Vamvakari, Iliana Evangelou, Ioanna Panagiota Kalafati, Michail Kipouros, Rena I. Kosti, Arezina N. Kasti, Odysseas Androutsos
    memo - Magazine of European Medical Oncology.2023; 16(3): 200.     CrossRef
  • AIWW: a new nutrition-screening tool for the oncologic population
    Yi-Zhong Ge, Zhen-Ming Fu, Qi Zhang, Meng-Meng Song, Guo-Tian Ruan, Xi Zhang, Xiao-Wei Zhang, Xiang-Rui Li, Kang-Ping Zhang, Meng Tang, Xiao-Yue Liu, Ming Yang, Tong Liu, Hai-Lun Xie, He-Yang Zhang, Zi-Wen Wang, Chun-Lei Hu, Shi-Qi Lin, Rui Zhang, Hong-Xi
    Science China Life Sciences.2023; 66(8): 1831.     CrossRef
  • Validation of a telephone‐based administration of the simplified nutritional appetite questionnaire
    Binh Duong Thai, Jürgen M. Bauer, Annette Eidam, Jane Durga, Stefan Grund, Thomas Mross, Petra Benzinger
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(4): 1848.     CrossRef
  • Faeces from malnourished colorectal cancer patients accelerate cancer progression
    Xu Chao, Zhang Lei, Liu Hongqin, Wang Ziwei, Li Dechuan, Du Weidong, Xu Lu, Chen Haitao, Zhang Bo, Ju Haixing, Yao Qinghua
    Clinical Nutrition.2022; 41(3): 632.     CrossRef
  • Influence of cognitive function and nurse support on malnutrition risk in nursing home residents
    Annamária Pakai, Emese Havasi‐Sántha, Erzsébet Mák, Orsolya Máté, Dorina Pusztai, Noémi Fullér, Miklós Zrínyi, András Oláh
    Nursing Open.2021; 8(4): 1805.     CrossRef
  • Effectiveness of Oral Nutritional Supplements on Older People with Anorexia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Mengqi Li, Si Zhao, Shuang Wu, Xiufen Yang, Hui Feng
    Nutrients.2021; 13(3): 835.     CrossRef
  • Loss of appetite in patients with amyotrophic lateral sclerosis is associated with weight loss and anxiety/depression
    Yajun Wang, Shan Ye, Lu Chen, Lu Tang, Dongsheng Fan
    Scientific Reports.2021;[Epub]     CrossRef
  • Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study
    Sue Youn Kim, Jae Moon Yun, Ji-Won Lee, Young Gyu Cho, Kyung-Hwan Cho, Yong Gyu Park, Belong Cho
    Clinical Therapeutics.2021; 43(10): 1757.     CrossRef
  • Development of Korean Frailty Index for Primary Care (KFI-PC) and Its Criterion Validity
    Chang Won Won, Yunhwan Lee, Seoyoon Lee, Miji Kim
    Annals of Geriatric Medicine and Research.2020; 24(2): 125.     CrossRef
  • The Simplified Nutritional Appetite Questionnaire (SNAQ) as a Screening Tool for Risk of Malnutrition: Optimal Cutoff, Factor Structure, and Validation in Healthy Community-Dwelling Older Adults
    Sabrina Lau, Kalene Pek, Justin Chew, Jun Pei Lim, Noor Hafizah Ismail, Yew Yoong Ding, Matteo Cesari, Wee Shiong Lim
    Nutrients.2020; 12(9): 2885.     CrossRef
  • 8,140 View
  • 205 Download
  • 15 Web of Science
  • 14 Crossref
Close layer
Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy
Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, In Gyu Hwang, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, In Sook Woo, Soojung Hong, Tae-Yong Kim, Ji Yeon Baek, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Hun-Mo Ryoo, Kyung Hee Lee, Jee Hyun Kim
Cancer Res Treat. 2019;51(3):1249-1256.   Published online January 2, 2019
DOI: https://doi.org/10.4143/crt.2018.451
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to prospectively validate the Korean Cancer Study Group Geriatric Score (KG)-7, a novel geriatric screening tool, in older patients with advanced cancer planned to undergo first-line palliative chemotherapy.
Materials and Methods
Participants answered the KG-7 questionnaire before undergoing geriatric assessment (GA) and first-line palliative chemotherapy. The performance of KG-7 was evaluated by calculating the sensitivity (SE), specificity (SP), positive and negative predictive value (PPV and NPV), balanced accuracy (BA), and area under the curve (AUC).
Results
The baseline GA and KG-7 results were collected from 301 patients. The median age was 75 years (range, 70 to 93 years). Abnormal GA was documented in 222 patients (73.8%). Based on the ≤ 5 cut-off value of KG-7 for abnormal GA, abnormal KG-7 score was shown in 200 patients (66.4%). KG-7 showed SE, SP, PPV, NPV, and BA of 75.7%, 59.7%, 84.4%, 46.0%, and 67.7%, respectively; AUC was 0.745 (95% confidence interval, 0.687 to 0.803). Furthermore, patients with higher KG-7 scores showed significantly longer survival (p=0.006).
Conclusion
KG-7 appears to be adequate in identifying patients with abnormal GA prospectively. Hence, KG-7 can be a useful screening tool for Asian countries with limited resources and high patient volume.

Citations

Citations to this article as recorded by  
  • Comparison of two frailty screening tools in older patients with colorectal cancer
    Han Zhao, Xinlin Lu, Senshuang Zheng, Danmei Wei, Lizhong Zhao, Yuan Wang, Geertruida H. de Bock, Wenli Lu
    BMC Geriatrics.2023;[Epub]     CrossRef
  • Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
    In Gyu Hwang, Minsuk Kwon, Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, Jin Young Kim, Su-Jin Koh, Yoon Ho Ko, Seong Hoon Shin, Soojung Hong, Tae-Yong Kim, Sun Young Kim, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Kyung Hee Lee,
    Cancers.2021; 13(2): 331.     CrossRef
  • A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy
    Koung Jin Suh, Seonghae Yoon, Jin Won Kim, Seo Hyun Yoon, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
    Journal of Geriatric Oncology.2021; 12(6): 922.     CrossRef
  • Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients with Solid Cancers: Protocol for a Danish prospective cohort study (PROGNOSIS-G8)
    Helena Møgelbjerg Ditzel, Ann-Kristine Weber Giger, Cecilia Margareta Lund, Henrik Jørn Ditzel, Afsaneh Mohammadnejad, Per Pfeiffer, Jesper Ryg, Trine Lembrecht Jørgensen, Marianne Ewertz
    Journal of Geriatric Oncology.2021; 12(8): 1270.     CrossRef
  • The Globalization of Geriatric Oncology: From Data to Practice
    Ravindran Kanesvaran, Supriya Mohile, Enrique Soto-Perez-de-Celis, Harpreet Singh
    American Society of Clinical Oncology Educational Book.2020; (40): e107.     CrossRef
  • 9,521 View
  • 180 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer
Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee
Cancer Res Treat. 2019;51(1):223-239.   Published online October 19, 2018
DOI: https://doi.org/10.4143/crt.2018.073
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC).
Materials and Methods
Thiswas a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians.
Results
Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline)were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e., ≥ 11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy.
Conclusion
This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patientswith advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Citations

Citations to this article as recorded by  
  • Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
    Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, J. Wang, X. Zhou, A. Gnanasakthy, K. Taylor, A. Yusuf, I. Majer, A. Jamotte, Y.-K. Kang
    ESMO Gastrointestinal Oncology.2024; 6: 100095.     CrossRef
  • Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
    Adán Rodríguez-Gonzalez, Alberto Carmona-Bayonas, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mónica Antoñanzas-Basa, David Lorente-Estelles, María Jose Corral, Manuel González-Moya, Oscar Alfredo Castillo-Trujillo, Emilio Esteban, Paula Jiménez-
    Clinical and Translational Oncology.2023; 25(12): 3492.     CrossRef
  • Reminiscence therapy-based care program alleviates anxiety and depression, as well as improves the quality of life in recurrent gastric cancer patients
    Xing Wu, Weiwei Zhang
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors
    Eun Mi Lee, Paula Jiménez-Fonseca, Rocio Galán-Moral, Sara Coca-Membribes, Ana Fernández-Montes, Elena Sorribes, Esmeralda García-Torralba, Laura Puntí-Brun, Mireia Gil-Raga, Juana Cano-Cano, Caterina Calderon
    Current Oncology.2023; 30(10): 9205.     CrossRef
  • Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review
    Cara Ghiglieri, Martin Dempster, Sam Wright, Lisa Graham-Wisener
    BMC Palliative Care.2023;[Epub]     CrossRef
  • Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
    Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang
    Gastric Cancer.2021; 24(1): 156.     CrossRef
  • Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial
    Kazumasa Fujitani, Kohei Shitara, Atsuo Takashima, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hisashi Hosaka, Yoshito Komatsu, Ken Shimada, Ryohei Kawabata, Hideki Ohdan, Yasuhiro Kode
    Gastric Cancer.2021; 24(2): 467.     CrossRef
  • Quality-of-Life Assessment in Patients Receiving Palliative Chemotherapy: Call for Action
    Maheswari Senthil
    Annals of Surgical Oncology.2021; 28(1): 7.     CrossRef
  • Impact of gastric cancer treatment on quality of life of patients
    Kerstin Schütte, Christian Schulz, Kristina Middelberg-Bisping
    Best Practice & Research Clinical Gastroenterology.2021; 50-51: 101727.     CrossRef
  • Influencing Factors and Effects of Treatment on Quality of Life in Patients With Gastric Cancer—A Systematic Review
    Sophia Kristina Rupp, Andreas Stengel
    Frontiers in Psychiatry.2021;[Epub]     CrossRef
  • Chronological changes in quality of life and body composition after gastrectomy for locally advanced gastric cancer
    Ki Bum Park, Ji Yeon Park, Seung Soo Lee, Ho Young Chung, Oh Kyoung Kwon
    Annals of Surgical Treatment and Research.2020; 98(5): 262.     CrossRef
  • Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
    Hannah Christina Puhr, Eleonore Pablik, Anna Sophie Berghoff, Gerd Jomrich, Sebastian Friedrich Schoppmann, Matthias Preusser, Aysegül Ilhan-Mutlu
    ESMO Open.2020; 5(2): e000623.     CrossRef
  • 11,461 View
  • 235 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
Dong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, Keunchil Park, Hoon-Kyo Kim, Joung Soon Jang, Bong-Seog Kim, Jin-Hyoung Kang, Kyung Hee Lee, Sang-We Kim, Hun Mo Ryoo, Jin-Soo Kim, Ki Hyeong Lee, Jung Hye Kwon, Jin-Hyuk Choi, Sang Won Shin, Seokyung Hahn, Dae Seog Heo
Cancer Res Treat. 2019;51(1):119-127.   Published online March 12, 2018
DOI: https://doi.org/10.4143/crt.2018.019
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This randomized phase III study was designed to compare the efficacy and safety of irinote-can plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC).
Materials and Methods
Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m2 intravenously on days 1 and 8+cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m2 intravenously on days 1, 2, 3+cisplatin 70 mg/m2 intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival.
Results
A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP.
Conclusion
The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC.

Citations

Citations to this article as recorded by  
  • Factors associated with posttraumatic stress and anxiety among the parents of babies admitted to neonatal care: a systematic review
    Reem Malouf, Sian Harrison, Victoria Pilkington, Charles Opondo, Chris Gale, Alan Stein, Linda S. Franck, Fiona Alderdice
    BMC Pregnancy and Childbirth.2024;[Epub]     CrossRef
  • Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort
    Hassan Abdelilah Tafenzi, Farah Choulli, Edwin Kelly Haag, Anass Baladi, Ismail Essaadi, Rhizlane Belbaraka
    Translational Oncology.2024; 47: 102015.     CrossRef
  • Clinical Benefits of new Systemic Therapy for Small‐Cell Lung Cancer Over Two Decades: A Cross‐Sectional Study
    Yuejing Chen, Honghong Liu, Shaohua Bai, Xuejiao Han, Fei Jin, Bo Cui
    The Clinical Respiratory Journal.2024;[Epub]     CrossRef
  • Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis
    Paul O. Odeniran, Paradise Madlala, Nompumelelo P. Mkhwanazi, Mahmoud E. S. Soliman
    Cancers.2024; 16(22): 3802.     CrossRef
  • Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies
    Ying Liu, Lin Wu, Dingzhi Huang, Qiming Wang, Chen Yang, Li Zhou, Shuguang Sun, Xiaomei Jiang, Ying Cheng
    Cancer Treatment and Research Communications.2024; 42: 100869.     CrossRef
  • Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis
    Guo Lin, Zhuoran Yao, Kai Kang, Hui Wang, Ren Luo, You Lu
    Cancer Medicine.2023; 12(9): 10230.     CrossRef
  • Therapeutic strategy analysis of patients with advanced stage high‐grade neuroendocrine cervical cancer: A real‐world multicenter study
    Yuanyuan Zhang, Yi Huang, Suiyu Luo, Lin Li, Hongying Yang, Ziyi Wang, Yongmei Peng, Manni Huang, Jusheng An, Xi Yang, Jing Wang, Chunmei Li, Lingying Wu
    International Journal of Gynecology & Obstetrics.2022; 158(3): 722.     CrossRef
  • Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer
    Christine M. Cramer‐van der Welle, Franz M. N. H. Schramel, Bas J. M. Peters, John W. G. van Putten, Olaf H. Klungel, Harry J. M. Groen, Ewoudt M. W. van de Garde
    Pharmacoepidemiology and Drug Safety.2021; 30(4): 445.     CrossRef
  • Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database
    Jung Soo Lee, Seoree Kim, Soo-Yoon Sung, Yeo Hyung Kim, Hyun Woo Lee, Ji Hyung Hong, Yoon Ho Ko
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
    Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, Hironori Sagara
    Current Oncology.2021; 28(2): 1094.     CrossRef
  • Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study
    Seo Ree Kim, Ji Hyung Hong, Soo-Yoon Sung, Yeo Hyung Kim, Sang Hoon Chun, Hyun Woo Lee, Jung Soo Lee, Yoon Ho Ko
    BMC Cancer.2021;[Epub]     CrossRef
  • Clinical significance of the cachexia index in patients with small cell lung cancer
    Se-Il Go, Mi Jung Park, Gyeong-Won Lee
    BMC Cancer.2021;[Epub]     CrossRef
  • Sevens Cases of Neuroendocrine Carcinoma of the Nasal and Paranasal Sinuses
    Ichiro Sekine, Kan Kishibe, Miki Takahara, Hiroaki Katada, Tatsuya Hayashi, Yasuaki Harabuchi
    Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology).2021; 60(2): 169.     CrossRef
  • Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
    Millie Das, Sukhmani K. Padda, Jared Weiss, Taofeek K. Owonikoko
    Advances in Therapy.2021; 38(11): 5431.     CrossRef
  • Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
    Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
    Current Oncology.2021; 28(6): 4894.     CrossRef
  • Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive‐stage disease small cell lung cancer: Results from a randomized controlled trial
    Gyeong‐Won Lee, Se‐Il Go, Dong‐Wan Kim, Hoon‐Gu Kim, Joo‐Hang Kim, Ho Jung An, Joung Soon Jang, Bong‐Seog Kim, Seokyung Hahn, Dae Seog Heo
    Thoracic Cancer.2020; 11(1): 62.     CrossRef
  • IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
    Mi-Sook Lee, Kyungsoo Jung, Ji-Young Song, Min-Jung Sung, Sung-Bin Ahn, Boram Lee, Doo-Yi Oh, Yoon-La Choi
    Molecular Therapy - Oncolytics.2020; 16: 188.     CrossRef
  • Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
    Panpan Zhang, Jie Li, Jian Li, Xiaotian Zhang, Jun Zhou, Xicheng Wang, Zhi Peng, Lin Shen, Ming Lu
    Cancer.2020; 126(S9): 2086.     CrossRef
  • Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
    Hao Chen, Nobuyuki Horita, Kentaro Ito, Hideyuki Nagakura, Yu Hara, Nobuaki Kobayash, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen


    Feiwen Liu, Shaozhang Zhou, Liping Tan, Huiqin Jiang, Yucong Huang
    Cancer Management and Research.2020; Volume 12: 10341.     CrossRef
  • Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer
    Ting Zhou, Zhonghan Zhang, Fan Luo, Yuanyuan Zhao, Xue Hou, Tingting Liu, Kai Wang, Hongyun Zhao, Yan Huang, Li Zhang
    JAMA Network Open.2020; 3(10): e2015748.     CrossRef
  • Thérapie ciblée et immunothérapie du cancer bronchique à petites cellules
    J.-L. Pujol, C. Goze, C. Pujol, B. Roch
    Revue des Maladies Respiratoires Actualités.2019; 11(3): 315.     CrossRef
  • Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
    Fei Xu, Xiaoli Ren, Yuan Chen, Qianxia Li, Ruichao Li, Yu Chen, Shu Xia
    BMC Cancer.2018;[Epub]     CrossRef
  • Traitement médical du cancer bronchique à petites cellules : peut-on sortir de l’aire du cisplatine–étoposide ?
    Jean-Louis Pujol, Benoît Roch, Camille N. Pujol, Catherine Goze
    Bulletin du Cancer.2018;[Epub]     CrossRef
  • 12,789 View
  • 517 Download
  • 29 Web of Science
  • 24 Crossref
Close layer
S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
Choong-kun Lee, Minkyu Jung, Hyo Song Kim, Inkyung Jung, Dong Bok Shin, Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Moon Hee Lee, Bong-Seog Kim, Kyung Hee Lee, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2019;51(1):1-11.   Published online February 5, 2018
DOI: https://doi.org/10.4143/crt.2018.028
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients.
Materials and Methods
Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m2 /day on days 1-14 plus docetaxel 35 mg/m2 on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m2 /day on days 1-14 plus cisplatin 60 mg/m2 on day 1) every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate.
Results
Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was approved based on the CLASSIC study, itwas decided to close the study early. With a median follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not significantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4 adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned treatment.
Conclusion
Our findings suggest that SP or DS is an effective and tolerable option for patients with curatively resected stage III gastric cancer.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
    Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer
    Lili Liu, Li Sun, Ning Zhang, Cheng-gong Liao, Haichuan Su, Jie Min, Yang Song, Xue Yang, Xiaofeng Huang, Dongxu Chen, Yu Chen, Hong-wei Zhang, Helong Zhang
    International Journal of Hyperthermia.2022; 39(1): 239.     CrossRef
  • Comment on “post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial”
    Qiang Hu, Yuanshui Sun
    Clinical Nutrition.2021; 40(3): 1438.     CrossRef
  • THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
    A. A. Bobryshev, M. M. Davudov, M. N. Narimanov, S. B. Polycarpova, V. Y. Kirsanov, V. N. Blindar
    Siberian journal of oncology.2021; 20(1): 133.     CrossRef
  • Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
    Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
    Surgical Oncology.2021; 38: 101599.     CrossRef
  • Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
    Chih-Chieh Yen, Yan-Shen Shan, Ying-Jui Chao, Ting-Kai Liao, I-Shu Chen, Hsuan-Yi Huang, I-Ting Liu, Chia-Jui Yen
    BMC Cancer.2021;[Epub]     CrossRef
  • Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?
    Ina Valeria Zurlo, Michele Basso, Antonia Strippoli, Maria Alessandra Calegari, Armando Orlandi, Alessandra Cassano, Mariantonietta Di Salvatore, Giovanna Garufi, Emilio Bria, Giampaolo Tortora, Carlo Barone, Carmelo Pozzo
    Cancers.2020; 12(7): 1749.     CrossRef
  • A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer
    Long Ge, Liangying Hou, Qingxia Yang, Yiting Wu, Xiue Shi, Jiang Li, Kehu Yang
    Medicine.2019; 98(7): e14478.     CrossRef
  • Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
    Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Cancers.2019; 11(4): 530.     CrossRef
  • COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
    Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Cutting-edge evidence of adjuvant treatments for gastric cancer
    Dai Shimizu, Mitsuro Kanda, Yasuhiro Kodera, Junichi Sakamoto
    Expert Review of Gastroenterology & Hepatology.2018; 12(11): 1109.     CrossRef
  • 13,146 View
  • 591 Download
  • 23 Web of Science
  • 11 Crossref
Close layer
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
Yoon Ji Choi, Hye Sook Kim, Se Hoon Park, Bong-Seog Kim, Kyoung Ha Kim, Hyo Jin Lee, Hong Suk Song, Dong-Yeop Shin, Ha Young Lee, Hoon-Gu Kim, Kyung Hee Lee, Jae Lyun Lee, Kyong Hwa Park
Cancer Res Treat. 2018;50(4):1252-1259.   Published online January 2, 2018
DOI: https://doi.org/10.4143/crt.2017.438
AbstractAbstract PDFPubReaderePub
Purpose
Fibroblast growth factor (FGF) signals are important in carcinogenesis and progression of prostate cancer. Dovitinib is an oral, pan-class inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and fibroblast growth factor receptor (FGFR). We evaluated the efficacy and toxicity of dovitinib in men with metastatic castration resistant prostate cancer (mCRPC).
Materials and Methods
This study was a single-arm, phase II, open-label, multicenter trial of dovitinib 500 mg/day (5-days-on/2-days-off schedule). The primary endpointwas 16-week progression-free survival (PFS). Secondary endpoints were overall survival (OS), toxicity and prostate-specific antigen (PSA) response rate. Biomarker analyses for VEGFR2, FGF23, and FGFR2 using multiplex enzyme-linked immunosorbent assay was performed.
Results
Forty-four men were accrued from 11 hospitals. Eighty percent were post-docetaxel. Median PSA was 100 ng/dL, median age was 69, 82% had bone metastases, and 23% had liver metastases. Median cycles of dovitinibwas 2 (range, 0 to 33). Median PFSwas 3.67 months (95% confidence interval [CI], 1.36 to 5.98) and median OS was 13.70 months (95% CI, 0 to 27.41). Chemotherapy-naïve patients had longer PFS (17.90 months; 95% CI, 9.23 to 28.57) compared with docetaxel-treated patients (2.07 months; 95% CI, 1.73 to 2.41; p=0.001) and the patients with high serum VEGFR2 level over median level (7,800 pg/mL) showed longer PFS compared with others (6.03 months [95% CI, 4.26 to 7.80] vs. 1.97 months [95% CI, 1.79 to 2.15], p=0.023). Grade 3 related adverse events were seen in 40.9% of patients. Grade 1-2 nausea, diarrhea, fatigue, anorexia, and all grade thrombocytopenia are common.
Conclusion
Dovitinib showed modest antitumor activity with manageable toxicities in men with mCRPC. Especially, patients who were chemo-naïve benefitted from dovitinib.

Citations

Citations to this article as recorded by  
  • Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR
    Manish Chaudhary, Shubham Kumar, Paranjeet Kaur, Sanjeev Kumar Sahu, Amit Mittal
    Mini-Reviews in Medicinal Chemistry.2024; 24(7): 721.     CrossRef
  • Impact of cell plasticity on prostate tumor heterogeneity and therapeutic response
    Maddison Archer
    American Journal of Clinical and Experimental Urology.2024; 12(6): 331.     CrossRef
  • Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
    Alessio Ardizzone, Valentina Bova, Giovanna Casili, Alberto Repici, Marika Lanza, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Salvatore Cuzzocrea, Emanuela Esposito, Irene Paterniti
    Cells.2023; 12(7): 1002.     CrossRef
  • Case Report of a Glioma Patient with Homozygous Missense Amino Acid Substitution in KDR Gene
    Kalyan Ram Uppaluri, Himavanth Reddy Kambalachenu, Hima Jyothi Challa, Saadvik Raghuram Y., Deepak Sharma, Ramya Gadicherla, Srinivas Ketavath, Kalyani Palasamudram, Sri Manjari K.
    Indian Journal of Medical and Paediatric Oncology.2023; 44(03): 356.     CrossRef
  • FGFR families: biological functions and therapeutic interventions in tumors
    Qing Liu, Jiyu Huang, Weiwei Yan, Zhen Liu, Shu Liu, Weiyi Fang
    MedComm.2023;[Epub]     CrossRef
  • Targeting transforming growth factor‐ß signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin
    Devesh Tewari, Anu Priya, Anusha Bishayee, Anupam Bishayee
    Clinical and Translational Medicine.2022;[Epub]     CrossRef
  • Evaluation of the therapeutic potential of masitinib and expression of its specific targets c‐Kit, PDGFR‐α, PDGFR‐β, and Lyn in canine prostate cancer cell lines
    Katharina Klose, Eva‐Maria Packeiser, José‐Luis Granados‐Soler, Marion Hewicker‐Trautwein, Hugo Murua Escobar, Ingo Nolte
    Veterinary and Comparative Oncology.2022; 20(3): 641.     CrossRef
  • Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy
    Elizabeth Liow, Nicholas Howard, Chol-Hee Jung, Bernard Pope, Bethany K. Campbell, Anne Nguyen, Michael Kerger, Jonathan B. Ruddle, Angelyn Anton, Benjamin Thomas, Kevin Chu, Philip Dundee, Justin S. Peters, Anthony J. Costello, Andrew S. Ryan, Christophe
    Clinical Genitourinary Cancer.2022; 20(5): 452.     CrossRef
  • There are gremlins in prostate cancer
    Laura A. Sena, W. Nathaniel Brennen, John T. Isaacs
    Nature Cancer.2022; 3(5): 530.     CrossRef
  • Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
    Yundong He, Weidong Xu, Yu-Tian Xiao, Haojie Huang, Di Gu, Shancheng Ren
    Signal Transduction and Targeted Therapy.2022;[Epub]     CrossRef
  • Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
    Ankit Kumar Singh, Adarsh Kumar, Harshwardhan Singh, Pankaj Sonawane, Harshali Paliwal, Suresh Thareja, Prateek Pathak, Maria Grishina, Mariusz Jaremko, Abdul-Hamid Emwas, Jagat Pal Yadav, Amita Verma, Habibullah Khalilullah, Pradeep Kumar
    Pharmaceuticals.2022; 15(9): 1071.     CrossRef
  • The FGF/FGFR system in the physiopathology of the prostate gland
    Arianna Giacomini, Elisabetta Grillo, Sara Rezzola, Domenico Ribatti, Marco Rusnati, Roberto Ronca, Marco Presta
    Physiological Reviews.2021; 101(2): 569.     CrossRef
  • Signaling Pathways That Control Apoptosis in Prostate Cancer
    Amaal Ali, George Kulik
    Cancers.2021; 13(5): 937.     CrossRef
  • A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
    Fionnuala Crowley, Michelle Sterpi, Conor Buckley, Lauren Margetich, Shivani Handa, Zach Dovey
    Research and Reports in Urology.2021; Volume 13: 457.     CrossRef
  • Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
    F.J. Sherida H. Woei-A-Jin, Nir I. Weijl, Mark C. Burgmans, Arantza Fariña Sarasqueta, J. Tom van Wezel, Martin N.J.M. Wasser, Minneke J. Coenraad, Jacobus Burggraaf, Susanne Osanto
    The Oncologist.2021; 26(10): 854.     CrossRef
  • Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment
    Peiyuan Zhang, Xiaohui Liu, Daniel Abegg, Toru Tanaka, Yuquan Tong, Raphael I. Benhamou, Jared Baisden, Gogce Crynen, Samantha M. Meyer, Michael D. Cameron, Arnab K. Chatterjee, Alexander Adibekian, Jessica L. Childs-Disney, Matthew D. Disney
    Journal of the American Chemical Society.2021; 143(33): 13044.     CrossRef
  • Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer
    Clara H. Lee, Ann M. Decker, Frank C. Cackowski, Russell S. Taichman
    Cell Biology and Toxicology.2020; 36(2): 115.     CrossRef
  • Brivanib, a multitargeted small‐molecule tyrosine kinase inhibitor, suppresses laser‐induced CNV in a mouse model of neovascular AMD
    Lele Li, Manhui Zhu, Wenli Wu, Bai Qin, Jiayi Gu, Yuanyuan Tu, Jianing Chen, Dong Liu, Yunwei Shi, Xiaojuan Liu, Aimin Sang, Dongmei Ding
    Journal of Cellular Physiology.2020; 235(2): 1259.     CrossRef
  • In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells
    Arabinda Das, Jaime L. Martinez Santos, Mohammed Alshareef, Guilherme Bastos Ferreira Porto, Libby Kosnik Infinger, William A. Vandergrift, Scott M. Lindhorst, Abhay K. Varma, Sunil J. Patel, David Cachia
    Cancer Investigation.2020; 38(6): 349.     CrossRef
  • Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma
    Ling Zhang, Xia Niu, Yanghui Bi, Heyang Cui, Hongyi Li, Xiaolong Cheng
    Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
  • Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer


    Adam M. Kase, John A. Copland, Winston Tan
    OncoTargets and Therapy.2020; Volume 13: 10499.     CrossRef
  • Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review)
    Hong Luo, Tao Zhang, Peng Cheng, Dong Li, Oleksandr Ogorodniitchouk, Chaimaa Lahmamssi, Ge Wang, Meiling Lan
    Oncology Letters.2020; 20(3): 2525.     CrossRef
  • Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers
    Yi-Han Chiu, Yi-Yen Lee, Kuo-Chin Huang, Cheng-Chi Liu, Chen-Si Lin
    Journal of Oncology.2019; 2019: 1.     CrossRef
  • Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: a systematic review and meta-analysis
    Niko Kemi, Maarit Eskuri, Joonas H. Kauppila
    Scientific Reports.2019;[Epub]     CrossRef
  • Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors
    Dan Wang, Li Yang, Weina Yu, Yi Zhang
    Expert Opinion on Investigational Drugs.2019; 28(10): 903.     CrossRef
  • A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance
    Jacqueline Olender, Bi-Dar Wang, Travers Ching, Lana X. Garmire, Kaitlin Garofano, Youngmi Ji, Tessa Knox, Patricia Latham, Kenneth Nguyen, Johng Rhim, Norman H. Lee
    Molecular Cancer Research.2019; 17(10): 2115.     CrossRef
  • Recent Advances in Prostate Cancer Treatment and Drug Discovery
    Ekaterina Nevedomskaya, Simon J. Baumgart, Bernard Haendler
    International Journal of Molecular Sciences.2018; 19(5): 1359.     CrossRef
  • 11,145 View
  • 246 Download
  • 29 Web of Science
  • 27 Crossref
Close layer
Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives
Su-Jin Koh, Shinmi Kim, JinShil Kim, Bhumsuk Keam, Dae Seog Heo, Kyung Hee Lee, Bong-Seog Kim, Jee Hyun Kim, Hye Jung Chang, Sun Kyung Baek
Cancer Res Treat. 2018;50(2):614-623.   Published online July 3, 2017
DOI: https://doi.org/10.4143/crt.2016.446
AbstractAbstract PDFPubReaderePub
Purpose
The aims of this study were to explore how oncologists and resident physicians practice end-of-life (EOL) discussions and to solicit their opinions on EOL discussions as a means to improve the quality of EOL care.
Materials and Methods
A survey questionnaire was developed to explore the experiences and opinions about EOL discussions among oncologists and residents. Descriptive statistics, the t test, and the chisquare test were performed for the analyses.
Results
A total of 147 oncologists and 229 residents participated in this study. The study respondents reported diverse definitions of “terminal state,” and mostrespondents tried to disclose the patient’s condition to the patient and/or family members. Both groups were involved in EOL care discussions, with a rather low satisfaction level (57.82/100). The best timing to initiate discussionwas consideredwhen metastasis or disease recurrence occurred orwhen withdrawal of chemotherapy was anticipated. Furthermore, the study respondents suggested that patients and their family members should be included in the EOL discussion. Medical, legal, and ethical knowledge and communication difficulties along with practical issues were revealed as barriers and facilitators for EOL discussion.
Conclusion
This study explored various perspectives of oncologists and resident physicians for EOL discussion. Since the Life-Sustaining-Treatment Decision-Making Act will be implemented shortly in Korea, now is the time for oncologists and residents to prepare themselves by acquiring legal knowledge and communication skills. To achieve this, education, training, and clinical tools for healthcare professionals are required.

Citations

Citations to this article as recorded by  
  • Physicians are over optimistic in recognizing inpatients’ survival and palliative care needs: a large-scale multi-center study in Taiwan
    C -M Huang, S -J Huang, T -Y Wu, Y -C Chen, S -H Hsiao, D Chu
    QJM: An International Journal of Medicine.2024; 117(3): 195.     CrossRef
  • The quality of dying and death of patients with cancer from Shanghai in China from the perspective of healthcare providers: A cross-sectional study
    Jiawei Min, Peihao Liu, Kaifeng Xiao, Zhe Huang, Xiaobin Lai
    International Journal of Nursing Sciences.2024; 11(2): 179.     CrossRef
  • Issues and implications of the life-sustaining treatment decision act: comparing the data from the survey and clinical data of inpatients at the end-of-life process
    Eunjeong Song, Dongsoon Shin, Jooseon Lee, Seonyoung Yun, Minjeong Eom, Suhee Oh, Heejung Lee, Jiwan Lee, Rhayun Song
    BMC Medical Ethics.2024;[Epub]     CrossRef
  • Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study
    Hyeon-Su Im, Insook Lee, Shinmi Kim, Jong Soo Lee, Ju-Hee Kim, Jae Young Moon, Byung Kyu Park, Kyung Hee Lee, Myung Ah Lee, Sanghoon Han, Yoonki Hong, Hyeyeoung Kim, Jaekyung Cheon, Su-Jin Koh
    BMC Medical Ethics.2023;[Epub]     CrossRef
  • Barriers and facilitators that hospital clinicians perceive to discuss the personal values, wishes, and needs of patients in palliative care: a mixed-methods systematic review
    Sita de Vries, Mary-Joanne Verhoef, Sigrid Cornelia Johanna Maria Vervoort, Yvette Milene van der Linden, Saskia Cornelia Constantia Maria Teunissen, Everlien de Graaf
    Palliative Care and Social Practice.2023;[Epub]     CrossRef
  • Association Among End-Of-Life Discussions, Cancer Patients’ Quality of Life at End of Life, and Bereaved Families’ Mental Health
    Yoko Hayashi, Kazuki Sato, Masahiro Ogawa, Yoshiro Taguchi, Hisashi Wakayama, Aya Nishioka, Chikako Nakamura, Kaoru Murota, Ayumi Sugimura, Shoko Ando
    American Journal of Hospice and Palliative Medicine®.2022; 39(9): 1071.     CrossRef
  • Difficulties Facing Junior Physicians and Solutions Toward Delivering End-of-Life Care for Patients with Cancer: A Nationwide Survey in Japan
    Soichiro Okamoto, Yu Uneno, Natsuki Kawashima, Shunsuke Oyamada, Yusuke Hiratsuka, Keita Tagami, Manabu Muto, Tatsuya Morita
    Palliative Medicine Reports.2022; 3(1): 255.     CrossRef
  • The silent transition from curative to palliative treatment: a qualitative study about cancer patients’ perceptions of end-of-life discussions with oncologists
    A. Kitta, A. Hagin, M. Unseld, F. Adamidis, T. Diendorfer, E. K. Masel, K. Kirchheiner
    Supportive Care in Cancer.2021; 29(5): 2405.     CrossRef
  • Advance Care Planning in Asia: A Systematic Narrative Review of Healthcare Professionals’ Knowledge, Attitude, and Experience
    Diah Martina, Cheng-Pei Lin, Martina S. Kristanti, Wichor M. Bramer, Masanori Mori, Ida J. Korfage, Agnes van der Heide, Carin C.D. van der Rijt, Judith A.C. Rietjens
    Journal of the American Medical Directors Association.2021; 22(2): 349.e1.     CrossRef
  • Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
    Shin Hye Yoo, Wonho Choi, Yejin Kim, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2021; 53(2): 584.     CrossRef
  • Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act
    Hyeyeong Kim, Hyeon-Su Im, Kyong Og Lee, Young Joo Min, Jae-Cheol Jo, Yunsuk Choi, Yoo Jin Lee, Daseul Kang, Changyoung Kim, Su-Jin Koh, Jaekyung Cheon
    BMC Palliative Care.2021;[Epub]     CrossRef
  • Act on Decisions on Life-Sustaining Treatment and Timing of Referral to Hospice
    Han-na Ju, Seung Hun Lee, Yun-Jin Kim, Sang-Yeoup Lee, Jeong-Gyu Lee, Yu-Hyeon Yi, Young-Hye Cho, Young-Jin Tak, Hye-Rim Hwang, Eun-Ju Park, Young-In Lee
    Korean Journal of Family Practice.2021; 11(5): 331.     CrossRef
  • Nature of Discussions about Systemic Therapy Discontinuation or Hospice among Patients, Families, and Palliative Care Clinicians during Care for Incurable Cancer: A Qualitative Study
    Lara Traeger, Chelsea Rapoport, Emily Wright, Areej El-Jawahri, Joseph A. Greer, Elyse R. Park, Vicki A. Jackson, Jennifer S. Temel
    Journal of Palliative Medicine.2020; 23(4): 542.     CrossRef
  • Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
    Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2020; 52(3): 917.     CrossRef
  • Advance care planning in Asian culture
    Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng
    Japanese Journal of Clinical Oncology.2020; 50(9): 976.     CrossRef
  • Differences in perspectives of pediatricians on advance care planning: a cross-sectional survey
    In Gyu Song, Sung Han Kang, Min Sun Kim, Cho Hee Kim, Yi Ji Moon, Jung Lee
    BMC Palliative Care.2020;[Epub]     CrossRef
  • Feasibility of a team based prognosis and treatment goal discussion (T-PAT) with women diagnosed with advanced breast cancer
    Mary M. Step, Gretchen A. Ferber, Catherine Downs-Holmes, Paula Silverman
    Patient Education and Counseling.2019; 102(1): 77.     CrossRef
  • Attitudes of the General Public, Cancer Patients, Family Caregivers, and Physicians Toward Advance Care Planning: A Nationwide Survey Before the Enforcement of the Life-Sustaining Treatment Decision-Making Act
    Hye Yoon Park, Young Ae Kim, Jin-Ah Sim, Jihye Lee, Hyewon Ryu, Jung Lim Lee, Chi Hoon Maeng, Jung Hye Kwon, Yu Jung Kim, Eun Mi Nam, Hyun-Jeong Shim, Eun-Kee Song, Kyung Hae Jung, Eun Joo Kang, Jung Hun Kang, Young Ho Yun
    Journal of Pain and Symptom Management.2019; 57(4): 774.     CrossRef
  • Family-clinician communication in the ICU and its relationship to psychological distress of family members: A cross-sectional study
    Minjeong Jo, Mi-Kyung Song, George J. Knafl, Linda Beeber, Yang-Sook Yoo, Marcia Van Riper
    International Journal of Nursing Studies.2019; 95: 34.     CrossRef
  • Implementation of Antimicrobial Stewardship Programs in End-of-Life Care
    Ki Tae Kwon
    Infection & Chemotherapy.2019; 51(2): 89.     CrossRef
  • Facilitators and Barriers to Oncologists’ Conduct of Goals of Care Conversations
    Dena Schulman-Green, Jenny J. Lin, Cardinale B. Smith, Shelli Feder, Nina A. Bickell
    Journal of Palliative Care.2018; 33(3): 143.     CrossRef
  • Clinical characteristics and survival outcomes of terminally ill patients undergoing withdrawal of mechanical ventilation
    Yu-Shin Hung, Shu-Hui Lee, Chia-Yen Hung, Chao-Hui Wang, Chen-Yi Kao, Hung-Ming Wang, Wen-Chi Chou
    Journal of the Formosan Medical Association.2017;[Epub]     CrossRef
  • 9,837 View
  • 267 Download
  • 22 Web of Science
  • 22 Crossref
Close layer
Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
Ki Sun Jung, Su Jin Lee, Se Hoon Park, Jae-Lyun Lee, Se-Hoon Lee, Jae Yun Lim, Jung Hun Kang, Suee Lee, Sun Young Rha, Kyung Hee Lee, Ho Young Kim, Ho Yeong Lim
Cancer Res Treat. 2018;50(2):488-494.   Published online May 22, 2017
DOI: https://doi.org/10.4143/crt.2016.584
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC.
Materials and Methods
Patientswith locally advanced or metastatic nccRCC, exceptfor collecting duct or sarcomatoid type, received 800 mg/day of pazopanib daily until progression of disease or intolerable toxicity. One cyclewas defined as 4weeks and tumorresponsewas evaluated every two cycles. The primary objective was overall response rate (ORR).
Results
A total of 29 eligible patients were enrolled at nine centers in Korea from December 2012 and September 2014. The median age of the patients was 58 years (range, 27 to 76 years) and 21 patients (72%) were male. Regarding histology type, 19 patients had papillary, three had chromophobe, two had unclassified and five had unknown non-clear cell type. Of 28 evaluable patients, eight achieved a confirmed partial response with ORR of 28%. The median progression-free survival was 16.5 months (95% confidence interval, 10.9 to 22.1) and median overall survival was not reached. Sixteen patients (55%) experienced treatment-related toxicity of grade 3 or more, but most adverse events were overcome through dose reduction and delay.
Conclusion
In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC.

Citations

Citations to this article as recorded by  
  • Systemic therapy for non–clear cell renal cell carcinomas: A systematic review
    Balqees Ara, Anum Babar, Durkho Atif, Bushra Ghafoor, Mustafa Shah, Syed Maaz Abdullah, Danish Safi, Amir Kamran
    Journal of Oncology Pharmacy Practice.2025; 31(1): 128.     CrossRef
  • Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
    Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
    International Journal of Cancer.2024; 154(6): 947.     CrossRef
  • Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
    Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves e Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P. Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andra
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Papillary Renal Cell Carcinoma: Current Evidence and Future Directions
    Albert Jang, Charbel S. Hobeika, Shilpa Gupta
    Kidney Cancer.2024; 8(1): 61.     CrossRef
  • Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
    Hasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, Nargız Majidova, Tugay Avci, Halil Göksel Güzel, Caner Kapar, Mehmet Uzun, Perihan Perkin, Fahri Akgül, Saadet Sim Yildirim, Seda Sali, Anil Yildiz, Seher Nazli Kazaz, Engin Hendem, Murat Arcagok, G
    Journal of Chemotherapy.2024; : 1.     CrossRef
  • Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective
    Gaetano Pezzicoli, Vittoria Musci, Federica Ciciriello, Francesco Salonne, Paola Cafforio, Nicoletta Lionetti, Anna Ragno, Mimma Rizzo
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis
    Yaping Zhang, Jian Chen, Xiaoyan Wang, Hui Wang, Xiaoli Chen, Jianfeng Hong, Hongming Fang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma
    Floriane Izarn, Benoît Allignet, Romane Gille, Helen Boyle, Eve-Marie Neidhardt, Sylvie Négrier, Aude Fléchon
    Clinical Genitourinary Cancer.2023; 21(2): e35.     CrossRef
  • SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
    María José Méndez-Vidal, Martin Lázaro Quintela, Nuria Lainez-Milagro, Begoña Perez-Valderrama, Cristina Suárez Rodriguez, José Ángel Arranz Arija, Ignacio Peláez Fernández, Enrique Gallardo Díaz, Julio Lambea Sorrosal, Aránzazu González-del-Alba
    Clinical and Translational Oncology.2023; 25(9): 2732.     CrossRef
  • Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium
    Cihan Erol, Emre Yekedüz, Deniz Tural, Serdar Karakaya, Nihan Şentürk Öztaş, Gökhan Uçar, Saadettin Kılıçkap, İsmail Ertürk, Özlem Nuray Sever, Çağatay Arslan, Ahmet Küçükarda, Orçun Can, Özlem Balvan, Satı Coşkun Yazgan, Mustafa Özgüroğlu, Berna Öksüzoğl
    Urologia Internationalis.2023; 107(6): 595.     CrossRef
  • The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non‐clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database
    Tomoyuki Koguchi, Sei Naito, Shingo Hatakeyama, Kazuyuki Numakura, Yumina Muto, Renpei Kato, Takahiro Kojima, Yoshihide Kawasaki, Kento Morozumi, Shuya Kandori, Sadafumi Kawamura, Hiroyuki Nishiyama, Akihiro Ito, Tomonori Habuchi, Wataru Obara, Chikara Oh
    Cancer Medicine.2023; 12(22): 20677.     CrossRef
  • Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
    Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Pay
    Journal of the National Comprehensive Cancer Network.2022; 20(1): 71.     CrossRef
  • Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma
    Jason R. Brown, Adam Calaway, Erik Castle, Jorge Garcia, Pedro C. Barata
    Kidney Cancer.2022; 6(1): 53.     CrossRef
  • Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches
    Niloofar Khoshdel Rad, Maryam Vahidyeganeh, Mahsa Mohammadi, Anastasia Shpichka, Peter Timashev, Nikoo Hossein-Khannazer, Massoud Vosough
    International Journal of Translational Medicine.2022; 2(4): 555.     CrossRef
  • Systemic Therapies for the Management of Non–Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds
    Panagiotis Zoumpourlis, Giannicola Genovese, Nizar M. Tannir, Pavlos Msaouel
    Clinical Genitourinary Cancer.2021; 19(2): 103.     CrossRef
  • Comprehensive review of chromophobe renal cell carcinoma
    Rohan Garje, Dean Elhag, Hesham A Yasin, Luna Acharya, Daniel Vaena, Laila Dahmoush
    Critical Reviews in Oncology/Hematology.2021; 160: 103287.     CrossRef
  • A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
    Chelsea K. Osterman, Tracy L. Rose
    Kidney Cancer.2020; 4(1): 15.     CrossRef
  • Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
    Ivana Puliafito, Alessio Russo, Dorotea Sciacca, Caterina Puglisi, Dario Giuffrida
    Journal of Medical Case Reports.2020;[Epub]     CrossRef
  • On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
    Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier
    American Society of Clinical Oncology Educational Book.2020; (40): 418.     CrossRef
  • Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
    Melissa Bersanelli, Matteo Brunelli, Letizia Gnetti, Umberto Maestroni, Sebastiano Buti
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • Management of Metastatic Renal Cell Carcinoma with Variant Histologies
    Ronan Flippot, Vijay Damarla, Bradley A. McGregor
    Urologic Clinics of North America.2020; 47(3): 319.     CrossRef
  • Discovery of Pyrido[3′,2′:5,6]thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors
    Silvia Salerno, Elisabetta Barresi, Aída Nelly García-Argáez, Sabrina Taliani, Francesca Simorini, Giorgio Amendola, Stefano Tomassi, Sandro Cosconati, Ettore Novellino, Federico Da Settimo, Anna Maria Marini, Lisa Dalla Via
    ACS Medicinal Chemistry Letters.2019; 10(4): 457.     CrossRef
  • Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
    Nieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, Hannah Dzimitrowicz, Jarred Burkart, Daniel M Geynisman, Archana Balakrishnan, I Alex Bowman, Rohit Jain, Walter Stadler, Yousef Zakharia, Vivek Narayan, Benoit Beuselinck, Rana R McKay, Abhishek Tri
    The Lancet Oncology.2019; 20(4): 581.     CrossRef
  • Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas
    Keiichi Ito
    International Journal of Urology.2019; 26(9): 868.     CrossRef
  • Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
    Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, Jae Lyun Lee
    BMC Urology.2019;[Epub]     CrossRef
  • Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
    Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
    Cancer Research and Treatment.2019; 51(4): 1578.     CrossRef
  • The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review
    Gregory T. Sneed, Sukdong Lee, Jamie N. Brown, Julia M. Hammond
    Clinical Genitourinary Cancer.2019; 17(6): 419.     CrossRef
  • A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non–clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus
    Inkeun Park, Se Hoon Lee, Jae Lyun Lee
    Clinical Genitourinary Cancer.2018; 16(5): e997.     CrossRef
  • Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan
    Keiichi Ito, Shuji Mikami, Katsunori Tatsugami, Naoya Masumori, Nobuo Shinohara, Tsunenori Kondo, Shotaro Nakanishi, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba, Naoto Kuroda, Yoshihiko Tomita, Hideyasu Matsuyama, Tetsuro Onishi, Tomoyasu Tsushima, Hayaka
    Clinical Genitourinary Cancer.2018; 16(6): e1201.     CrossRef
  • 10,726 View
  • 491 Download
  • 37 Web of Science
  • 29 Crossref
Close layer
A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians
Do Yeun Kim, Jin Seok Ahn, Kyung Hee Lee, Young Chul Kim, Juneyoung Lee, Si-Young Kim
Cancer Res Treat. 2014;46(2):131-140.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.131
AbstractAbstract PDFPubReaderePub
Purpose

Although cancer pain is prevalent, under-treatment still remains a problem. Knowledge of and compliance with guidelines for management of cancer pain were analyzed for exploration of physician-related barriers to cancer pain management. In addition, physicians' knowledge and its correlation with cancer pain control were audited.

Materials and Methods

From July 8 to December 2, 2010, a nationwide survey of house staff enquired about their knowledge of cancer pain control guidelines, and the medical records of patients under their care were analyzed.

Results

In total, 180 physicians participated in the study. Their average score for knowledge was 14.6 (range, 7 to 19; maximum possible, 20). When the knowledge score was divided into low, medium, and high scores, patients receiving care from physicians with high levels of knowledge tended to have better cancer pain control (p<0.001). Of the total patients with severe pain, 19.5% were not prescribed strong opioids, and 40% were not prescribed any medication for breakthrough pain.

Conclusion

Physicians' knowledge of guidelines for control of cancer pain showed an association with improvement of pain management. Overall adherence to the guidelines was lacking. Continuous interventions such as education and audits regarding cancer pain control guidelines for physician are needed.

Citations

Citations to this article as recorded by  
  • Compliance with the breakthrough cancer pain European guidelines and impact on patients' quality of life: an observational prospective study
    Paolo Bossi, Tatiana Pietrzyńska, César Margarit Ferri, Irene Mansilla, Valeria Tellone, Sara Fioravanti, Giorgio Di Loreto, Alessandro Comandini
    Frontiers in Pain Research.2024;[Epub]     CrossRef
  • A Survey of Knowledge and Barriers of Healthcare Professionals toward Opioid Analgesics in Cancer Pain Management
    Nehad M. Ayoub, Malak Jibreel, Khawla Nuseir, Ghaith M. Al-Taani, Manish Gupta
    International Journal of Clinical Practice.2022; 2022: 1.     CrossRef
  • Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice
    Paolo Bossi, Yolanda Escobar, Federico Pea
    Frontiers in Pain Research.2022;[Epub]     CrossRef
  • Ozono y COVID-19: bases fisiológicas y sus posibilidades terapéuticas según el estadio evolutivo de la infección por SARS-Cov-2.
    Marcos Edgar Fernández Cuadros, María Jesús Albaladejo Florin, Sandra Alava Rabasa, Daiana Peña Lora, Olga Susana Pérez Moro
    Revista de la Sociedad Española del Dolor.2021;[Epub]     CrossRef
  • Comparing Methadone Rotation to Consensus Opinion
    Michael A. Smith, Kyle C. Quirk, D'Anna C. Saul, Phillip E. Rodgers, Maria J. Silveira
    Journal of Pain and Symptom Management.2020; 59(1): 116.     CrossRef
  • Physician’s Attitude toward Treating Breakthrough Cancer Pain in Korea
    Min Seok Seo, Jae Yong Shim, Youn Seon Choi, Do Yeun Kim, In Gyu Hwang, Sun Kyung Baek, Jin Young Shin, Juneyoung Lee, Chang Geol Lee
    The Korean Journal of Hospice and Palliative Care.2017; 20(1): 18.     CrossRef
  • Commentary on “A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians”
    Kieran Walsh
    Cancer Research and Treatment.2014; 46(4): 425.     CrossRef
  • 12,896 View
  • 106 Download
  • 6 Web of Science
  • 7 Crossref
Close layer
A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy
Hee Yeon Lee, Hoon-Kyo Kim, Kyung Hee Lee, Bong-Seog Kim, Hong Suk Song, Sung Hyun Yang, Joon Hee Kim, Yeul Hong Kim, Jong Gwang Kim, Sang-We Kim, Dong-Wan Kim, Si-Young Kim, Hee Sook Park
Cancer Res Treat. 2014;46(1):19-26.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.19
AbstractAbstract PDFPubReaderePub
PURPOSE
This study was conducted to evaluate the efficacy and safety of azasetron compared to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting.
MATERIALS AND METHODS
This study was a multi-center, prospective, randomized, double-dummy, double-blind and parallel-group trial involving 12 institutions in Korea between May 2005 and December 2005. A total of 265 patients with moderately and highly emetogenic chemotherapy were included and randomly assigned to either the azasetron or ondansetron group. All patients received azasetron (10 mg intravenously) and dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with placebo of ondansetron (orally every 12 hours), and the ondansetron group received ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 2-6.
RESULTS
Over days 2-6, the effective ratio of complete response in the azasetron and ondansetron groups was 45% and 54.5%, respectively (95% confidence interval, -21.4 to 2.5%). Thus, the non-inferiority of azasetron compared with ondansetron in delayed chemotherapy-induced nausea and vomiting was not proven in the present study. All treatments were well tolerated and no unexpected drug-related adverse events were reported. The most common adverse events related to the treatment were constipation and hiccups, and there were no differences in the overall incidence of adverse events.
CONCLUSION
In the present study, azasetron showed inferiority in the control of delayed chemotherapy-induced nausea and vomiting compared with ondansetron whereas safety profiles were similar between the two groups.

Citations

Citations to this article as recorded by  
  • Influence of ABCB1 genetic polymorphisms on the antiemetic response to ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients in a tertiary care hospital
    Ayyar Porkodi, Deepak Gopal Shewade, Goud Alladi Charanraj
    Current Issues in Pharmacy and Medical Sciences.2023; 36(3): 129.     CrossRef
  • Hiccups in Cancer Patients Receiving Chemotherapy: A Cross-Sectional Study
    Mevlüde Ergen, Fatma Arikan, Rüya Fırat Çetin
    Journal of Pain and Symptom Management.2021; 62(3): e85.     CrossRef
  • A Fast and Validated HPLC Method for the Simultaneous Analysis of Five 5-HT3 Receptor Antagonists via the Quantitative Analysis of Multicomponents by a Single Marker
    Fuchao Chen, Baoxia Fang, Peng Li, Sicen Wang, Amr M. Mahmoud
    International Journal of Analytical Chemistry.2021; 2021: 1.     CrossRef
  • Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
    Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report
    Hiroki Hosokawa, Hideaki Shimoda, Takayuki Ishii
    YAKUGAKU ZASSHI.2019; 139(4): 647.     CrossRef
  • Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration
    Bao-Xia Fang, Fu-Chao Chen, Dan Zhu, Jun Guo, Lin-Hai Wang
    Oncotarget.2017; 8(63): 106249.     CrossRef
  • Gender Differences in Hiccup Patients: Analysis of Published Case Reports and Case-Control Studies
    Gyeong-Won Lee, Rock Bum Kim, Se Il Go, Hyun Seop Cho, Seung Jun Lee, David Hui, Eduardo Bruera, Jung Hun Kang
    Journal of Pain and Symptom Management.2016; 51(2): 278.     CrossRef
  • Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
    Bishal Gyawali, Bishesh Sharma Poudyal, Mahesh Iddawela
    Journal of Global Oncology.2016; 2(3): 145.     CrossRef
  • Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
    K. Jordan, F. Jahn, M. Aapro
    Annals of Oncology.2015; 26(6): 1081.     CrossRef
  • 12,002 View
  • 66 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Effect of Dose Escalation with Single Opioid, Fentanyl Matrix in Patients Not Controlling Cancer Pain: A Multicenter, Prospective, Observational Study in Korea
Sung Ae Koh, Kyung Hee Lee, Mi Jung Kim, Kyu Taek Lee, Seung Woo Park, Seung Hyun Nam, Hun Mo Ryoo
Cancer Res Treat. 2013;45(4):263-269.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.263
AbstractAbstract PDFPubReaderePub
PURPOSE
End-of-dose failure (EOD) is a clinically common observation and many cancer patients increase the frequency of opioid administration. Fentanyl matrix use is known to be effective in patients with chronic cancer pain. To measure the effectiveness of increase in a single dose of fentanyl matrix in patients whose pain was not controlled sufficiently, we perform this study.
MATERIALS AND METHODS
A multi-center, open-label, prospective, observational study was conducted in 30 hospitals in Korea, between August and December 2008.
RESULTS
A total of 452 patients were enrolled; 404 patients completed the study. The mean pain intensity decreased from 5.27 at the first visit to 3.37 at the end of the trial. There was a significant difference in pain intensity (p < 0.001) between the first and last visits. The percentage of pain intensity difference was 30.1%. The prevalence of EOD at the first visit was 73% from the 452 enrolled patients. After the use of fentanyl patch, EOD decreased from 73% to 56%. Pain intensity of patients experiencing EOD was 5.64 at the baseline compared to 4.27 in patients without EOD. On final visit, pain intensity in patients with and without EOD was 4.02 and 2.54, respectively. The observed adverse events were mainly nausea, asthenia, constipation and diarrhea.
CONCLUSION
This study demonstrated that increasing dose of fentanyl patch decreased pain intensity and decreased the rate of patients experiencing EOD. Thus, fentanyl patch may be an effective modality in cancer patients whose pain was previously not controlled sufficiently; the side effects were as could be expected with an opioid.
  • 11,946 View
  • 68 Download
Close layer
Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement
Byung Woog Kang, Joon Ho Moon, Yee Soo Chae, Soo Jung Lee, Jong Gwang Kim, Yeo-Kyeoung Kim, Je-Jung Lee, Deok-Hwan Yang, Hyeoung-Joon Kim, Jin Young Kim, Young Rok Do, Keon Uk Park, Hong Suk Song, Ki Young Kwon, Min Kyung Kim, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Hwak Kim, Sang Kyun Sohn
Cancer Res Treat. 2013;45(2):112-117.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.112
AbstractAbstract PDFPubReaderePub
PURPOSE
We investigated the clinical outcome of bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.
MATERIALS AND METHODS
A total of 567 consecutive patients with newly diagnosed DLBCL treated with rituximab-CHOP (RCHOP) between November 2001 and March 2010 were included in the current study. All of the patients underwent a BM study at the initial staging and the clinical characteristics and prognosis of these patients with or without BM involvement were analyzed retrospectively.
RESULTS
The total cohort included 567 patients. The overall incidence of BM involvement was 8.5%. With a median follow-up duration of 33.2 months (range, 0.1 to 80.7 months) for patients who were alive at the last follow-up, the five-year overall survival (OS) and event-free survival (EFS) rate in patients without BM involvement (76.3% and 67.5%, p<0.001) was statistically higher than that in patients with BM involvement (44.3% and 40.1%, p<0.001). In multivariate analysis, among total patients, BM involvement showed a significant association with OS and EFS. In univariate and multivariate analyses, even among stage IV patients, a significant association with worse EFS was observed in the BM involvement group.
CONCLUSION
BM involvement at diagnosis affected the survival of patients with DLBCL who received RCHOP. Although use of RCHOP can result in significant improvement of the therapeutic effect of DLBCL, BM involvement is still a negative prognostic factor of DLBCL patients in the era of rituximab.

Citations

Citations to this article as recorded by  
  • Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma
    Haruya Okamoto, Nobuhiko Uoshima, Ayako Muramatsu, Reiko Isa, Takahiro Fujino, Yayoi Matsumura-Kimoto, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Tsutomu Kobayashi, Eri Kawata, Hitoji Uchiyama, Junya Kuroda
    Diagnostics.2021; 11(9): 1724.     CrossRef
  • Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility
    Jeffrey W. Craig, Michael J. Mina, Jennifer L. Crombie, Ann S. LaCasce, David M. Weinstock, Geraldine S. Pinkus, Olga Pozdnyakova, Francesco Bertolini
    PLOS ONE.2018; 13(7): e0199708.     CrossRef
  • HIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era
    Maria Joao Baptista, Olga Garcia, Mireia Morgades, Eva Gonzalez-Barca, Pilar Miralles, Armando Lopez-Guillermo, Eugenia Abella, Miriam Moreno, Juan-Manuel Sancho, Evarist Feliu, Josep-Maria Ribera, Jose-Tomas Navarro
    AIDS.2015; 29(7): 811.     CrossRef
  • Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma
    José Carlos Jaime-Pérez, Carmen Magdalena Gamboa-Alonso, Alberto Vázquez-Mellado de Larracoechea, Marisol Rodríguez-Martínez, César Homero Gutiérrez-Aguirre, Luis Javier Marfil-Rivera, David Gómez-Almaguer
    Archives of Medical Research.2015; 46(6): 454.     CrossRef
  • 24,960 View
  • 63 Download
  • 4 Crossref
Close layer
Case Report
A Case of Spine Origin Chondroblastoma Metastasis to Lung
Se Hoon Sohn, Sung Aee Koh, Dong Geun Kim, Sung Woo Park, Kyung Hee Lee, Min Kyoung Kim, Jun Hyuk Choi, Myung Soo Hyun
Cancer Res Treat. 2009;41(4):241-244.   Published online December 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.4.241
AbstractAbstract PDFPubReaderePub

Chondroblastoma is a rare benign cartilaginous neoplasm that accounts for approximately 1% of all bone tumors and characteristically arises in the epiphysis of a long bone, particularly the humerus, tibia, and femur. Chondroblastoma can affect people of all ages. It is, however, most common in children and young adults between the ages of 10 and 20 years. Although most chondroblastomas are cured by limited surgical procedures, occasional lesions behave more aggressively and may even metastasis. In this case a young man with pulmonary metastatic chondroblastoma on spine is presented. Unlike previously published examples of metastatic chondroblastoma, these metastasis developed before any operative manipulation of the primary tumor. And primary tumor site was also unusual. The histologic characteristics of the primary, metastatic tumors were those of a conventional chondroblastoma.

Citations

Citations to this article as recorded by  
  • Chondroblastoma of Thoracic Vertebrae: a Case Report and Review of the Literature
    Alireza Tabibkhooei, Parisa Javadnia
    Indian Journal of Surgical Oncology.2024; 15(S1): 22.     CrossRef
  • Bone metastases from chondroblastoma: a rare pattern of metastatic disease in an adult
    Jennifer Murphy, Anish Patel, Simon Hughes, Petr Rehousek, John Drake, Vaiyapuri Sumathi, Rajesh Botchu, A. Mark Davies
    Skeletal Radiology.2024; 53(6): 1219.     CrossRef
  • Comprehensive Insights into Chondroblastoma Metastasis: Metastatic Patterns and Therapeutic Approaches
    Ramy Samargandi, Abrar Bafail, Louis-Romée Le Nail, Julien Berhouet
    Cancers.2024; 16(12): 2283.     CrossRef
  • Clinicopathological and Prognostic Characteristics in Spinal Chondroblastomas: A Pooled Analysis of Individual Patient Data From a Single Institute and 27 Studies
    Bo-Wen Zheng, Wei Huang, Fu-Sheng Liu, Tao-Lan Zhang, Xiao-Bin Wang, Jing Li, Guo-Hua Lv, Yi-Guo Yan, Ming-Xiang Zou
    Global Spine Journal.2023; 13(3): 713.     CrossRef
  • Chondroblastoma: clinicopathological analyses of 307 cases from a single institution in China and the diagnostic value of the H3F3 K36M mutant antibody
    Qianqian Zhao, Juan Tang, Yanli Luo, Jin Huang, Dingjun Hu, Jinyu Zhu, Ting Jiang, Huizhen Zhang, Zhiyan Liu
    Journal of Clinical Pathology.2023; 76(6): 367.     CrossRef
  • Clinicopathological characteristics and prognostic factors in axial chondroblastomas: a retrospective analysis of 61 cases and comparison with extra-axial chondroblastomas
    Bo-Wen Zheng, Bo-Yv Zheng, Hua-Qing Niu, Ming-Xiang Zou, Hai-Lin Wu, Ming Wang, Xue-Lin Li
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • Pulmonary Metastases of Chondroblastoma in a Pediatric Patient: A Case Report and Review of Literature
    Courtney Wing, Pankaj Watal, Monica Epelman, Juan Infante, Tushar Chandra
    Cureus.2022;[Epub]     CrossRef
  • Missed radiographic and clinical findings in a case of non-idiopathic scoliosis resulting from chondroblastoma
    Navraj S. Sagoo, Edward P. Southern, Andrew G. King, Matthew W. Stark, Lori A. McBride
    Spine Deformity.2021; 9(1): 297.     CrossRef
  • Sacral chondroblastoma — a rare location, a rare pathology: A case report and review of literature
    Bo-Wen Zheng, Hua-Qing Niu, Xiao-Bin Wang, Jing Li
    World Journal of Clinical Cases.2021; 9(20): 5709.     CrossRef
  • Chondroblastoma of the knee in a teenager
    Maitham Alkadumi, Neil Duggal, Sukhman Kaur, Joseph Dobtsis
    Radiology Case Reports.2021; 16(12): 3729.     CrossRef
  • Pediatric Chondroblastoma and the Need for Lung Staging at Presentation
    Alexandre Arkader, Amy Williams, Odion Binitie, Mihir M. Thacker, German L. Farfalli
    Journal of Pediatric Orthopaedics.2020; 40(9): e894.     CrossRef
  • Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy
    David I. Suster, Pawel Kurzawa, Azfar Neyaz, Jason A. Jarzembowski, Santiago Lozano-Calderon, Kevin Raskin, Joseph Schwab, Edwin Choy, Ivan Chebib, Vikram Deshpande
    American Journal of Surgical Pathology.2020; 44(12): 1581.     CrossRef
  • Histone H3K36M mutation and trimethylation patterns in chondroblastoma
    Chuanyong Lu, Daniel Ramirez, Sinchun Hwang, Achim Jungbluth, Denise Frosina, Peter Ntiamoah, John Healey, Guo Zhu, Wen Chen, Michael Klein, Meera Hameed
    Histopathology.2019; 74(2): 291.     CrossRef
  • Chondroblastoma of bone in extremities. - A single centre study of 177 cases
    M.K. Laitinen, J.D. Stevenson, S. Evans, A. Abudu, V. Sumathi, L.M. Jeys, M.C. Parry
    Journal of Bone Oncology.2019; : 100248.     CrossRef
  • Clinical features, treatments and long-term follow-up outcomes of spinal chondroblastoma: report of 13 clinical cases in a single center
    Qi Jia, Chao Liu, Jian Yang, Yong Ji, Haifeng Wei, Tielong Liu, Xinghai Yang, Cheng Yang, Jianru Xiao
    Journal of Neuro-Oncology.2018; 140(1): 99.     CrossRef
  • Chondroblastoma: An evaluation of the recurrences and functional outcomes following treatment
    Devrim Özer, Yavuz Arıkan, Volkan Gür, Cantay Gök, Yunus Emre Akman
    Acta Orthopaedica et Traumatologica Turcica.2018; 52(6): 415.     CrossRef
  • Condroblastoma óseo
    F. Sailhan, M. Bachy, B. Tomeno, V. Dumaine, A. Babinet, P. Anract
    EMC - Aparato Locomotor.2014; 47(1): 1.     CrossRef
  • Chondroblastoma of the Navicular Bone
    XiaoNa Li, ZhiGang Peng, JingPin Zhao, ZeKun Zhang
    Iranian Journal of Radiology.2014;[Epub]     CrossRef
  • Douleur de l’épaule révélant un chondroblastome huméral
    A. Zrig, M. Zrig, W. Mnari, H. El Mhabrech, R. Salem, A. Abid, M. Golli
    Archives de Pédiatrie.2014; 21(12): 1386.     CrossRef
  • Chondroblastoma of the Knee Treated with Resection and Osteochondral Allograft Reconstruction
    Judd Fitzgerald, Cory Broehm, David Chafey, Gehron Treme
    Case Reports in Orthopedics.2014; 2014: 1.     CrossRef
  • Chondroblastoma of the Lumbar Vertebra Associated with Cauda Equina Compression
    Yeap Ewe-Juan, Siow Yew-Siong, Deepak Ajit-Singh
    Journal of Orthopaedics, Trauma and Rehabilitation.2013; 17(2): 99.     CrossRef
  • A Massive Chondroblastoma in the Proximal Humerus Simulating Malignant Bone Tumors
    Ichiro Tonogai, Mitsuhiko Takahashi, Hiroaki Manabe, Toshihiko Nishisho, Seiji Iwamoto, Shoichiro Takao, Seiko Kagawa, Eiji Kudo, Natsuo Yasui
    Case Reports in Orthopedics.2013; 2013: 1.     CrossRef
  • 11,358 View
  • 80 Download
  • 22 Crossref
Close layer
Original Articles
Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee
Cancer Res Treat. 2009;41(1):12-18.   Published online March 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.1.12
AbstractAbstract PDFPubReaderePub
Purpose

Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.

Materials and Methods

One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1~5 every 4 weeks.

Results

At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.

Conclusion

Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.

Citations

Citations to this article as recorded by  
  • The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
    Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
    Cancer Research and Treatment.2025; 57(1): 39.     CrossRef
  • Quantum mechanical approaches and molecular docking analysis of platinum metal-based anticancer drugs Lobaplatin and Heptaplatin targeting cancer DNA - a comparative analysis
    Madhavi Sahadevan, Mullainathan Sundaram, Karunagaran Subramanian
    Chemical Physics Letters.2024; 842: 141191.     CrossRef
  • Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
    S. Shruthi, K. Bhasker Shenoy
    ChemistrySelect.2024;[Epub]     CrossRef
  • Recent Advances on Pt-Based Compounds for Theranostic Applications
    Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
    Molecules.2024; 29(15): 3453.     CrossRef
  • Hallmarks of anticancer and antimicrobial activities of corroles
    Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
    Drug Resistance Updates.2023; : 100931.     CrossRef
  • Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
    Dobrina Tsvetkova, Stefka Ivanova
    Molecules.2022; 27(8): 2466.     CrossRef
  • Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity
    Galdina V. Suárez-Moreno, Delia Hernández-Romero, Óscar García-Barradas, Óscar Vázquez-Vera, Sharon Rosete-Luna, Carlos A. Cruz-Cruz, Aracely López-Monteon, Jesús Carrillo-Ahumada, David Morales-Morales, Raúl Colorado-Peralta
    Coordination Chemistry Reviews.2022; 472: 214790.     CrossRef
  • Metalofármacos en la terapia contra el cáncer
    Elizabeth Márquez López, Esmeralda Sánchez Pavón, Rodolfo Peña Rodríguez, Delia Hernández Romero, José M. Rivera Villanueva, Raúl Colorado Peralta, David Morales Morales
    TECNOCIENCIA Chihuahua.2022; 16(3): e1010.     CrossRef
  • Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Dan Gibson
    Journal of Inorganic Biochemistry.2021; 217: 111353.     CrossRef
  • Monofunctional Platinum(II) Anticancer Agents
    Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang
    Pharmaceuticals.2021; 14(2): 133.     CrossRef
  • Pt(IV) Prodrugs with NSAIDs as Axial Ligands
    Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
    International Journal of Molecular Sciences.2021; 22(8): 3817.     CrossRef
  • Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Dan Gibson
    Journal of Inorganic Biochemistry.2019; 191: 77.     CrossRef
  • TOXview: a novel graphical presentation of cancer treatment toxicity profiles
    Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, E. Hugo van Herk, Jessy Joy van Kleef, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Acta Oncologica.2019; 58(8): 1138.     CrossRef
  • Photoactivated platinum-based anticancer drugs
    Muhammad Imran, Wagma Ayub, Ian S. Butler, Zia-ur-Rehman
    Coordination Chemistry Reviews.2018; 376: 405.     CrossRef
  • Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
    Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
    Cancer Chemotherapy and Pharmacology.2018; 81(6): 981.     CrossRef
  • An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
    Dimitris Bertsimas, Allison O’Hair, Stephen Relyea, John Silberholz
    Management Science.2016; 62(5): 1511.     CrossRef
  • Platinum(iv) anticancer prodrugs – hypotheses and facts
    Dan Gibson
    Dalton Transactions.2016; 45(33): 12983.     CrossRef
  • Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines
    Pavel Štarha, Zdeněk Trávníček, Lucia Pazderová, Zdeněk Dvořák
    Journal of Inorganic Biochemistry.2016; 162: 109.     CrossRef
  • VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells
    Sergey A. Shein, Ilya I. Kuznetsov, Tatiana O. Abakumova, Pavel S. Chelushkin, Pavel A. Melnikov, Anna A. Korchagina, Dmitry A. Bychkov, Irina F. Seregina, Mikhail A. Bolshov, Alexander V. Kabanov, Vladimir P. Chekhonin, Natalia V. Nukolova
    Molecular Pharmaceutics.2016; 13(11): 3712.     CrossRef
  • Condensations of single DNA molecules induced by heptaplatin and its chiral isomer
    Hong-Yan Zhang, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Peng-Ye Wang
    AIP Advances.2014;[Epub]     CrossRef
  • Nanocarriers for delivery of platinum anticancer drugs
    Hardeep S. Oberoi, Natalia V. Nukolova, Alexander V. Kabanov, Tatiana K. Bronich
    Advanced Drug Delivery Reviews.2013; 65(13-14): 1667.     CrossRef
  • Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
    Investigational New Drugs.2012; 30(3): 1224.     CrossRef
  • Cellular interactions of platinum drugs
    Ezequiel Wexselblatt, Eylon Yavin, Dan Gibson
    Inorganica Chimica Acta.2012; 393: 75.     CrossRef
  • What do we know about the reduction of Pt(IV) pro-drugs?
    Ezequiel Wexselblatt, Dan Gibson
    Journal of Inorganic Biochemistry.2012; 117: 220.     CrossRef
  • Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
    X.-L. Zhang, H.-J. Shi, S.-Z. Cui, Y.-Q. Tang, M.-C. Ba
    European Journal of Surgical Oncology (EJSO).2011; 37(6): 466.     CrossRef
  • The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
    Dalton Transactions.2010; 39(35): 8113.     CrossRef
  • 12,100 View
  • 114 Download
  • 26 Crossref
Close layer
Discrepant Views of Korean Medical Oncologists and Cancer Patients on Complementary and Alternative Medicine
Do Yeun Kim, Bong-Seog Kim, Kyung Hee Lee, Myung Ah Lee, Young Seon Hong, Sang Won Shin, Soon Nam Lee
Cancer Res Treat. 2008;40(2):87-92.   Published online June 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.2.87
AbstractAbstract PDFPubReaderePub
Purpose

This study was designed to evaluate the communication gap between Korean medical oncologists and cancer patients on complementary and alternative medicine (CAM).

Materials and Methods

Cross sectional studies utilized the responses of 59 medical oncologists and 211 patients. To understand the communication gap, perceived reasons and nondisclosure of CAM use, reactions of physicians to disclosure, and expectations for CAM were analyzed. Data were compared with use of the chi-squared test.

Results

Both medical oncologists and patients were in accord that CAM use would privde the patients with a feeling of hope. The medical oncologists believed more often than patients to attribute CAM use for control over medical care decisions, for the treatment of an incurable disease or as a nontoxic approach (p<0.05). Regarding reasons for nondisclosure, medical oncologists were more likely to think that physicians would not understand the use of CAM, discontinue treatment or disapprove of the use of CAM (p<0.0001). Patients attributed nondisclosure mainly to the lack of questioning about CAM. Medical oncologists were more likely to warn of the risks with CAM use and less likely to encourage the use of CAM than perceived by patients (p=0.01). Patients expected that CAM could cure disease, extend survival, relieve symptoms and improve the immune system or quality of life more often than medical oncologists (p<0.05).

Conclusion

Given the discrepant views of medical oncologists and patients on the use of CAM, medical oncologists should be aware of the discrepancies and attempt to resolve any differences.

Citations

Citations to this article as recorded by  
  • Use of decision aid to improve informed decision-making and communication with physicians on the use of oral complementary and alternative medicine (CAM) among cancer patients on chemotherapy treatment: a randomised controlled trial
    Wan-Qin Chong, Maria Jannet Mogro, Asrie Arsad, Bee-Choo Tai, Soo-Chin Lee
    Supportive Care in Cancer.2021; 29(7): 3689.     CrossRef
  • Discrepant Views of Oncologists and Cancer Patients on Complementary and Alternative Medicine in a Chinese General Hospital
    Geliang Yang, Huiqing Zhang, Zheng Gan, Yifu Fan, Wei Gu, Changquan Ling
    Integrative Cancer Therapies.2018; 17(2): 451.     CrossRef
  • Information and Training Needs Regarding Complementary and Alternative Medicine: A Cross-sectional Study of Cancer Care Providers in Germany
    Gudrun E. Klein, Corina Guethlin
    Integrative Cancer Therapies.2018; 17(2): 380.     CrossRef
  • China’s cancer patients’ perceptions, attitudes and participation in clinical trials of complementary and alternative medicine: A multi-center cross-sectional study
    Yifu Fan, Huiqing Zhang, Geliang Yang, Cheng Wu, Yuyu Guo, Changquan Ling
    European Journal of Integrative Medicine.2018; 19: 115.     CrossRef
  • National survey of China's oncologists' knowledge, attitudes, and clinical practice patterns on complementary and alternative medicine
    Geliang Yang, Richard Lee, Huiqing Zhang, Wei Gu, Peiying Yang, Changquan Ling
    Oncotarget.2017; 8(8): 13440.     CrossRef
  • Expected and perceived efficacy of complementary and alternative medicine: A comparison views of patients with cancer and oncologists
    Sang Hyuck Kim, Dong Wook Shin, You-Seon Nam, So Young Kim, Hyung-kook Yang, Be Long Cho, Keeho Park, Heui-Sug Jo, Chang-Yeol Yim, Sin Kam, Jong-Hyock Park
    Complementary Therapies in Medicine.2016; 28: 29.     CrossRef
  • Survey of Policies and Guidelines on Antioxidant Use for Cancer Prevention, Treatment, and Survivorship in North American Cancer Centers
    Gyeongyeon Hong, Jennifer White, Lihong Zhong, Linda E. Carlson
    Integrative Cancer Therapies.2015; 14(4): 305.     CrossRef
  • National Survey of US Oncologists' Knowledge, Attitudes, and Practice Patterns Regarding Herb and Supplement Use by Patients With Cancer
    Richard T. Lee, Andrea Barbo, Gabriel Lopez, Amal Melhem-Bertrandt, Heather Lin, Olufunmilayo I. Olopade, Farr A. Curlin
    Journal of Clinical Oncology.2014; 32(36): 4095.     CrossRef
  • Perception and attitude of Jordanian physicians towards complementary and alternative medicine (CAM) use in oncology
    Amal Al-Omari, Mohammad Al-Qudimat, Amid Abu Hmaidan, Luna Zaru
    Complementary Therapies in Clinical Practice.2013; 19(2): 70.     CrossRef
  • Investigation into the Use of Complementary and Alternative Medicine and Factors Affecting Use in Korean Patients with Brain Tumors
    Yong Soon Shin, Jeong A Lee, So Hyun Bae, Su Youn Lee, Min Kyeong Jang
    Journal of Korean Academy of Fundamentals of Nursing.2013; 20(2): 147.     CrossRef
  • Complementary and alternative medicine use and assessment of quality of life in Korean breast cancer patients: a descriptive study
    Eunyoung Kang, Eun Joo Yang, Sun-Mi Kim, Il Yong Chung, Sang Ah Han, Do-Hoon Ku, Soek-Jin Nam, Jung-Hyun Yang, Sung-Won Kim
    Supportive Care in Cancer.2012; 20(3): 461.     CrossRef
  • Validation of the Korean Integrative Medicine Attitude Questionnaire (IMAQ)
    Jung-Ha Kim, Jung-Bok Lee, Duk-Chul Lee
    Korean Journal of Family Medicine.2011; 32(3): 197.     CrossRef
  • 9,465 View
  • 54 Download
  • 12 Crossref
Close layer
A Multi-Center, Phase II Clinical Trial of Padexol™ (Paclitaxel) and Cisplatin for Patients Suffering with Advanced Gastric Cancer
Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Young Rok Do, Hong Suk Song, Won Sik Lee, Keon Uk Park, Jin Ho Baek, Jong Gwang Kim
Cancer Res Treat. 2005;37(6):349-353.   Published online December 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.6.349
AbstractAbstract PDFPubReaderePub
Purpose

We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for the patients suffering with advanced gastric adenocarcinoma.

Materials and Methods

39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol 175 mg/m2 was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m2 as an intravenous infusion on day 1, once every 3 weeks.

Results

Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild.

Conclusion

The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advanced gastric cancer.

Citations

Citations to this article as recorded by  
  • Effect of the Weekly Administration of Liposome–Paclitaxel Combined with S-1 on Advanced Gastric Cancer
    Lei Chen, Qiang Chen, Zhixiang Zhuang, Yusong Zhang, Jialong Tao, Liqin Shen, Xudong Shen, Zhigang Chen, Ji Wang, Minggao Zhu, Hui Wang
    Japanese Journal of Clinical Oncology.2014; 44(3): 208.     CrossRef
  • Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer
    Jin Young Kim, Young Rok Do, Keon Uk Park, Jong Gwang Kim, Yee Soo Chae, Min Kyoung Kim, Kyung Hee Lee, Hun Mo Ryoo, Sung Hwa Bae, Jin Ho Baek, Hong Suk Song
    Cancer Chemotherapy and Pharmacology.2011; 67(3): 527.     CrossRef
  • Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer
    Yuji Ueda, Hisakazu Yamagishi, Daisuke Ichikawa, Kazuma Okamoto, Eigo Otsuji, Jun Morii, Kinya Koizumi, Naoki Kakihara, Masataka Shimotsuma, Tetsuro Yamashita, Fumihiro Taniguchi, Hideki Aragane, Hiroshi Nishi, Yoshiki Itokawa, Satoshi Morita, Junichi Sak
    Gastric Cancer.2010; 13(3): 149.     CrossRef
  • TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin
    Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Won Sik Lee, Chang-Hak Sohn, Joo Seop Jung, Gab Chul Kim, Ho Young Chung, Wansik Yu
    Cancer Chemotherapy and Pharmacology.2009; 64(2): 355.     CrossRef
  • Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
    Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
    Japanese Journal of Clinical Oncology.2009; 39(4): 237.     CrossRef
  • A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
    Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
    Cancer Research and Treatment.2007; 39(1): 6.     CrossRef
  • Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
    Jong Gwang Kim, Sang Kyun Sohn, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Keon Uk Park, Jin Ho Baek, Won Sik Lee, Joo Seop Chung, Goon Jae Cho, Chang-Hak Sohn, Jung Soon Jang, Ho Young Chung, Wan
    Cancer Chemotherapy and Pharmacology.2007; 60(6): 863.     CrossRef
  • The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
    Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
    Cancer Research and Treatment.2006; 38(2): 66.     CrossRef
  • 10,239 View
  • 72 Download
  • 8 Crossref
Close layer
Effect of Combination Chemotherapy with Docetaxel Plus Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
Hee Jung Kang, Min Kyoung Kim, Young Gil Kim, Jae Lyun Lee, Kyung Hee Lee, Myung Soo Hyun, Sung Hwa Bae, Hun Mo Ryoo
Cancer Res Treat. 2003;35(4):299-303.   Published online August 31, 2003
DOI: https://doi.org/10.4143/crt.2003.35.4.299
AbstractAbstract PDF
PURPOSE
This study was conducted to evaluate the efficacy and safety of combination chemotherapy, with docetaxel and cisplatin, as a first line treatment for advanced non-small cell lung cancer.
MATERIALS AND METHODS
Between March 1998 and December 2001, 35 patients with advanced non-small cell lung cancer were enrolled in this study. The patients were treated at 3-week intervals, with one course of a regimen consisting of docetaxel (75 mg/m2 IV for 1 hours) on day 1 and cisplatin (60 mg/m2 IV) on day 2.
RESULTS
The median age of the patients was 60.3 years. Of the 35 patients, 20 and 15 had stage IIIb and stage IV diseases, respectively. A complete response was observed in 1 patient and partial response in 15, with an overall response rate of 46%. The overall median survival duration was 40.3+/-25.2 weeks. The median time to progression and response duration were 21.6+/-5.5 and 15.1+/-5.9 weeks, respectively. The survival duration was statistically significantly longer in the response group (50.6 weeks) than in the non-response group (31.6 weeks) (p<0.05). Of the hematological side effects, grades III and IV leukopenia were observed in 4.8% of patients. Grades III and IV nausea and vomiting were observed in 48.5%, and grades I and II neuropathy in 11.4% of the treated patients. These toxicities were well tolerable and reversible. There were no hypersensitivity reactions.
CONCLUSION
Docetaxel and cisplatin combination chemotherapy is relatively effective and safe in advanced non-small cell lung cancer patients.
  • 4,194 View
  • 34 Download
Close layer
Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target
Kyung Hee Lee, Myung Soo Hyun, Jae Ryong Kim
Cancer Res Treat. 2003;35(3):207-212.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.207
AbstractAbstract PDF
PURPOSE
Increased expression of the hepatocytes growth factor (HGF) receptor (c-Met) and urokinase type plasminogen activator (uPA) correlate with the development and metastasis of cancers. However, the mechanisms by which HGF/c-Met signaling mediate cancer progression and metastasis are unclear. Therefore, we investigated the roles of HGF/c-Met in tumor progression and metastasis in pancreatic cancer cell lines, L3.6PL and IMIN-PC2. MATERIALS AND METHODS: To see the functional c-Met protein, we were performed immunoprecipitation for functional c-Met protein. And also performed western bolot analysis and gel zymography for the functional uPA protein. To see the inhibition effects of uPAR monoclonal antibody on invasiveness of two pancreatic cancer cell lines, we were carried out standard two chamber invasion assay. RESULTS: At first, we observed the HGF-mediated c-Met phosphorylation and cell growth. c-Met phosphorylation was increased in the HGF-treated cells in a dose dependent manner. HGF resulted in increments of cell growth and ERK phosphorylation. HGF treatment increased the uPA expression and the uPA activity. A monoclonal antibody 3936, specific to uPAR receptor, inhibited HGF- mediated tumor cell invasion in a dose dependent manner.
CONCLUSION
These results suggest that functional c- Met and HGF/c-Met signaling up-regulate the activity of uPA and result in increments of invasion-metastasis in the pancreatic cancer cells.

Citations

Citations to this article as recorded by  
  • PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cells
    He Xu, Di Wu, Mingming Xiao, Yubin Lei, Yalan Lei, Xianjun Yu, Si Shi
    Science Advances.2024;[Epub]     CrossRef
  • Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor
    Kyung Hee Lee, Jae-Ryong Kim
    Experimental and Molecular Medicine.2009; 41(3): 180.     CrossRef
  • Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells
    Kyung Hee Lee, Sang Woon Kim, Jae-Ryong Kim
    Journal of Experimental & Clinical Cancer Research.2009;[Epub]     CrossRef
  • Cellular Mechanisms of Hepatocyte Growth Factor-Mediated Urokinase Plasminogen Activator Secretion by MAPK Signaling in Hepatocellular Carcinoma
    Kyung Hee Lee, Eun Young Choi, Myung Soo Hyun, Jong Ryul Eun, Byung Ik Jang, Tae Nyeun Kim, Heon Ju Lee, Dong Shik Lee, Sung Su Yun, Hong Jīn Kim, Jung Hye Kim, Jae-Ryong Kim
    Tumori Journal.2008; 94(4): 523.     CrossRef
  • Association of Extracellular Cleavage of E-Cadherin Mediated by MMP-7 with HGF-Induced in vitro Invasion in Human Stomach Cancer Cells
    K.H. Lee, E.Y. Choi, M.S. Hyun, B.I. Jang, T.N. Kim, S.W. Kim, S.K. Song, J.H. Kim, J.-R. Kim
    European Surgical Research.2007; 39(4): 208.     CrossRef
  • Hepatocyte Growth Factor/c-Met Signaling in Regulating Urokinase Plasminogen Activator in Human Stomach Cancer: A Potential Therapeutic Target for Human Stomach Cancer
    Kyung Hee Lee, Eun Young Choi, Myung Soo Hyun, Byung Ik Jang, Tae Nyeun Kim, Sang Woon Kim, Sun Kyo Song, Jung Hye Kim, Jae-Ryong Kim
    The Korean Journal of Internal Medicine.2006; 21(1): 20.     CrossRef
  • Expression of E-Cadherin and uPA and their Association with the Prognosis of Pancreatic Cancer
    Sang Joon Shin, Kyeong Ok Kim, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Keuk Jun Kim, Joon Hyuk Choi, Hong Seok Song
    Japanese Journal of Clinical Oncology.2005; 35(6): 342.     CrossRef
  • 3,590 View
  • 21 Download
  • 7 Crossref
Close layer
Overexpression of c-met Protein in Gastric Cancer and Role of uPAR as a Therapeutic Target
Hyun A Oh, Gu Lee, Hee Jung Kang, Yong Gil Kim, Sung Hwa Bae, Jae Lyun Lee, Kyung Hee Lee, Myung Soo Hyun, Dong Suk Kim
Cancer Res Treat. 2003;35(1):9-15.   Published online February 28, 2003
DOI: https://doi.org/10.4143/crt.2003.35.1.9
AbstractAbstract PDF
PURPOSE
One of the members of the tyrosine kinase receptor family is the protein product of the c-met proto-oncogene, which is the receptor for hepatocyte growth factor (HGF). HGF is known as a potent mitogen and motogen for many kinds of carcinoma cells, and has been found to simulate the growth and progression of gastric cancer cells through HGF-receptors. In addition, the urokinase-type plasminogen activator (uPA) and receptor (uPAR) also play important roles in the invasion and metastasis. MATERIALS AND METHODS: The expression of c-met protein was investigated using immunohistochemical staining of 50 paraffin embedded gastric cancers, and by measuring the serum uPAR levels, before and after an operation, in gastric cancer patients using an ELISA assay. RESULTS: Of the 50 cases, 32 (64%) expressed the c-met protein. The c-met protein expression was significantly correlated with the TNM staging (p<0.05), but the other prognostic factors were not significant variables. According to a Kaplan-Meier's plot, the one and three year overall survival rates were 94 and 70% in patients not expressing the c-met protein, and 81 and 33% in those that did, and the Survival curves revealed a significantly different prognosis (p=0.04). Elevated serum uPAR levels (> or=3257.8 pg/ml, control+/-mean 2SD) were observed in 9 (34.6%) of 26 gastric cancer patients, but in none of control subjects. Average serum uPAR levels were 2980.8+/-616.2 pg/ml before the operation and 2404.7+/-455.9 pg/ml after, and decreased significantly after surgical resection (p<0.05). The serum uPAR level correlated significantly with lymph node metastasis and vessel invasion (p<0.05) CONCLUSION: The expression of c-met protein, and the level of uPAR, may be prognostic factors in gastric cancer.

Citations

Citations to this article as recorded by  
  • Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer
    Lan-Mei Wang, Wei-Wei Zhang, Ying-Yang Qiu, Fang Wang
    World Journal of Gastrointestinal Oncology.2024; 16(6): 2781.     CrossRef
  • Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review
    Wu-Jie Wei, Ya-Li Hong, Yi Deng, Guan-Liang Wang, Jiang-Tao Qiu, Fang Pan
    World Journal of Gastrointestinal Oncology.2024; 16(8): 3397.     CrossRef
  • Human Triosephosphate Isomerase Is a Potential Target in Cancer Due to Commonly Occurring Post-Translational Modifications
    Sergio Enríquez-Flores, Ignacio De la Mora-De la Mora, Itzhel García-Torres, Luis A. Flores-López, Yoalli Martínez-Pérez, Gabriel López-Velázquez
    Molecules.2023; 28(16): 6163.     CrossRef
  • SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer
    Katia De Marco, Martina Lepore Signorile, Elisabetta Di Nicola, Paola Sanese, Candida Fasano, Giovanna Forte, Vittoria Disciglio, Antonino Pantaleo, Greta Varchi, Alberto Del Rio, Valentina Grossi, Cristiano Simone
    Cells.2023; 12(20): 2481.     CrossRef
  • MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
    Han S. Kim, Hong J. Chon, Hyunki Kim, Su‐Jin Shin, Volker Wacheck, Aaron M. Gruver, Jong S. Kim, Sun Y. Rha, Hyun C. Chung
    Journal of Surgical Oncology.2018; 117(8): 1679.     CrossRef
  • Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells
    Kyung Hee Lee, Jae-Ryong Kim
    Clinical & Experimental Metastasis.2009; 26(7): 685.     CrossRef
  • Association of Extracellular Cleavage of E-Cadherin Mediated by MMP-7 with HGF-Induced in vitro Invasion in Human Stomach Cancer Cells
    K.H. Lee, E.Y. Choi, M.S. Hyun, B.I. Jang, T.N. Kim, S.W. Kim, S.K. Song, J.H. Kim, J.-R. Kim
    European Surgical Research.2007; 39(4): 208.     CrossRef
  • 4,481 View
  • 29 Download
  • 7 Crossref
Close layer
Expressions of Multidrug Resistance-Related Genes in Gastric Cancer Tissue and Normal Gastric Mucosal Tissue
Seok Hun Song, Sang Woon Kim, Sun Kyo Song, Joon Hyuk Choi, Jeoung Hee Ha, Kyung Hee Lee
Cancer Res Treat. 2001;33(4):302-308.   Published online August 31, 2001
DOI: https://doi.org/10.4143/crt.2001.33.4.302
AbstractAbstract PDF
PURPOSE
This study was conducted to evaluate the expressions of the mdr1 gene and the MRP gene in tumor and adjacent normal gastric tissues.
MATERIALS AND METHODS
The specimens were obtained from 53 patients who had gastric cancer. None of these patients had received any kind of preoperative chemotherapy. The reverse transcription polymerase chain reaction and immunohistochemical stain were used to check the level of expressions of mRNAs and their associated proteins.
RESULTS
Highly positive expressions of mdr1 mRNA, MRP mRNA, p-glycoprotein, and MRP (multidrug resistance associated protein) were observed in the tumor and the adjacent normal tissues. Most tumor tissues coexpressed mdr1 mRNA and MRP mRNA significantly (p<0.001). The expression of these genes in the tumor was much stronger than in the normal counterpart tissues. The expression of the p-glycoprotein was correlated only with the pathological stage (p<0.05). MRP expression was correlated with lymph node metastasis (p<0.05).
CONCLUSION
Normal gastric tissue showed strong physiologic expressions of the mdr1 and MRP genes. Overexpressions of these genes were observed in gastric cancer tissue. The presence of multidrug resistance should be considered when planning anticancer chemotherapy for treating gastric cancer.
  • 3,719 View
  • 18 Download
Close layer
C-erbB-2 Protein Expression and Correlation in Sera and Tumors of Non-Small Cell Lung Cancer Patients
Hun Mo Ryoo, Sang Yeop Lee, Kyung Hee Lee, Myung Soo Hyun, Mi Jin Kim
J Korean Cancer Assoc. 2000;32(6):1100-1108.
AbstractAbstract PDF
PURPOSE
We have examined the expression of c-erbB-2 oncogene in sera and tissues of non-small cell lung cancer patients.
MATERIALS AND METHODS
Serum levels of c-erbB-2 protein were measured by an enzyme im munoassay in 55 patients with non-small cell lung cancer. Sera from patients with surgical therapy were evaluated again after surgery. Immunohistochemical staining was performed in 47 of these tumors.
RESULTS
Elevated levels (> or =45 U/mL, control mean 2SD) were observed in 15% of 55 non-small cell lung cancer patients, as compared with none of control subjects (p<0.05). The incidence of elevated level was higher in the adenocarcinoma than squamous cell carcinoma (22% vs 4%, p<0.01). The serum levels of c-erbB-2 protein decreased significantly after surgical tumor ablation (p<0.01). Tissue overexpression was obtained in 23/47 cases (49%). The incidence of c-erbB-2 overexpression was higher in the adenocarcinoma (73% vs 29%, p<0.005). No relationship was found between c-erbB-2 protein expression in serum and tumor tissue and clinicopathologic feature. Elevated serum c-erbB-2 levels predicted tissue overexpression with sensitivity 30% and specificity 96%. There was relationship between serum level and expression in tumor tissue of c-erbB-2 protein.
CONCLUSION
Serum and tissue levels of c-erbB-2 correlate in patients with non-small cell carcinoma. Serum c-erbB-2 protein may be a useful indicator of tumor burden in patients with non-small cell lung cancer.
  • 2,826 View
  • 17 Download
Close layer
A Case of Malignant Chondroid Syringoma with Lung Metastasis
Duck Hee Kim, Chan Woo Lee, Kyung Hee Lee, Myung Soo Hyun
J Korean Cancer Assoc. 1997;29(6):1119-1119.
AbstractAbstract PDF
Malignant chondroid syringoma, previously called "mixed tumor of the skin of the salivary gland type"is a fairly uncommon type of sweat gland tumor. Malignant chondroid syringoma frequently arises from the trunk and extremities, whereas the benign tumor is common to the head region. The present case occurred in a female. The malignant nature of the tumor was evident from repeated recurrences after excision of the mass and histopathological study. Lack of response to radiotherapy and chemotherapy led to widespread metastasis. We report a case of malignant chondroid syringoma with lung metastasis in a 39-year-old female patient and response to chemotherapy. We also reviewed the literatures of malignant chondroid syringoma.
  • 3,149 View
  • 37 Download
Close layer
Phase II clinical trial of recombinant human granulocyte colony-stimulating factor(fhG-CSF)(KRN8601) in advanced cancer patients with myelosuppression after chemotherapy
Jae Kyung Roh, Jin Hyuk Choi, Kyung Hee Lee, Hye Ran Lee, Nae Choon Yoo, Joo Hang Kim, Byung Soo Kim, Ho Young Lim
J Korean Cancer Assoc. 1993;25(5):725-735.
AbstractAbstract PDF
No abstract available.
  • 2,724 View
  • 15 Download
Close layer
Induction Chemotherapy and Surgery in Locally Advanced Stomach Cancer Showing Pancreas Involvement
Kyung Hee Lee, Jin Hyuk Choi, Sun Young Rha, Hye Ran Lee, Nae Chun Yoo, Ho Yeong Lim, Hyun Cheol Chung, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim
J Korean Cancer Assoc. 1994;26(3):377-385.
AbstractAbstract PDF
Gastric cancer is the most common malignancy in Korea. Cure for patients with gastric carcinoma can be achieved only by radical surgery. From August 1988 to May 1992, 25 patients with locally advanced unresectable gastric cancer received 5-FU(Fiuorouracil) + adriamydn + mitomycin-c or 5-FU + cisplatin based induction chemotherapy before surgem. The partial response rate after me- dian 3 cycles of induction cemotherapy was 52%, stable disease 12%, progressive disease 36%. Gastric resection was performed in 18 patients(72%); 13 patients(52%) underwent radical surgery and 5 patients(20%) underwent palliative surgery. Median survival of the patients who underwent cura- tive and palliative surgery was 24. 2 and 27 months, respectively. However, median survival of the patient who didnt undergo any surgery was only 6.5 months. The difference of median survival between curative surgery and none surgery group were significant statistically(P<0.03). Side effects of induction chemotherapy were acceptable and there were no life threatening toxicities In this study, half of the patients can undergo curative surgery after induction chemotherapy. We observe the long term survival in some patients after induction chemotherapy and surgery in loco-regionally advanced gsstric cancer. This therapeutic approch for the locally advanced stomach cancer seems to be feasible. But, prospective tandomized clinical trial is warranted in the future.
  • 2,758 View
  • 14 Download
Close layer
Phase 1b Clinical Trial and Pharmacokinetic Evaluation of Recombinant Human Granulocyte - Macrophage Colony
Jae Kyung Roh, Jin Hyuk Choi, Hyung Keun Roh, Sun Young Rha, Kyung Hee Lee, Hye Ran Lee, Jee Sook Hahn, Pum Soo Kim, Byung Soo Kim
J Korean Cancer Assoc. 1994;26(3):495-510.
AbstractAbstract PDF
To define the clinical safeties and hematologic effects of subcutaneously administered yeast- derived recombinant human granulocyte-macrophage colony stimulatina factor(rh GM-CSF, LBD-005h and to determine the maximally tolerated dose(MTD) and the pharmacokinetics. Sngle arm open non-randomized phase Ib study was carried in 15 cancer patients#(14 patients evaluable) with chemotherapy induced bone marrow depression. Rh GM-CSF by once-daily subcutaneous administration to groups of 3-6 patients at doses of 50, 100, 150, 250, 350, 500, 700 ug/m/d for 10 consecutive days was escalated unless greater than WHO grade III toxicites were observed. Intrapatient dose escalation was permitted. Clinical safeties and toxicities were observed with frequent hematologic monitering. Blood and urine were collected on day 1, and 8 of rh GM-CSF administration to evaluate the parmacokinetic parameters. Of the 15 enrolled patients, 14 patients were evaluable. Male to female ratio was 8: 6 with median age 32 y-o(10~70 y-o). Seven patients had osteosarcoma, 2 malignant lymphoma, 2 gastric carcinoma, 2 lung cancer and 1 had uterine leiomyosarcoma. The total administered cycles of rh GM-CSF were 24. At each dose step, 3 patients were treated with exception of 6 patients at 500 ug/m/d dose. At all the doses administered, fever and flue-like syndrome were common side effects. Grade I fever and flue-like syndrome 50~150 pg/m dose, and grade II fever flue- like syndrome were observed at the dose of grater than 250 u/m(2)/d dose. Even at the 700 ug/m(2)/ d dose, no greater than grade III toxicities were observed. Leucocytosis were dose dependent with 120-480% increment of baseline. Pharmacokinetic parameters are as follows; Cmax were dose dependent(0.42-11.7 ng/ml) with 2-4 hours of Tmax. AUC were also dose dependent(3.93~87.9ng.hr/ml) with sustained serum levels(0.2-2ng/ml) up to 12 hours after rh GM-CSF administration. Urinary excretion(0-24 hours) after GM-CSF was less than 1% of administered dose. Yeast-derived rh GM-CSF induces leucocytosis in the dose range of 150~500ug/m(2)/d with tolerable side effects. Subcutaneously administered rh GM-CSF has sustained serum levels up to 12 hours after administration. The doses of 150-500 ug/m/d would be appropriated for the further trials.
  • 2,796 View
  • 14 Download
Close layer
Concurrent Chemoradiotherapy of Locally Advanced Pancreatic Carcinoma and Effects of Hyperthemia
Myung Wook Kim, Kyung Hee Lee, Jae Bok Chung, Jin Sil Sung, Hye Ran Lee, Jin Hyuk Chil, Hyun Cheol Chung, Woo Cheol Kim, Ki Chang Keum, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim
J Korean Cancer Assoc. 1994;26(4):561-567.
AbstractAbstract PDF
The prognosis of pancreati cancer is still poor in spite of advance in surgical treatment and parasurgical adjuvant management. Eighteen patients with histologically confirmed locally advanced adenocarcinoma of the pancreas were received radiation(5000cGy)+5-FU. Patients were treated with 5-FU 200 mg/m IV bolus, 1 hour before irradiation each day. In some patients, within 30 minutes after radiotherapy, hyperthemia was added to above protocol two times weekly. Median survival of total patients was 9.5months. Median survival with RT+ 5-FU was 12.7months from the date of treatment. Median survival with hyperthemia added group was 7.6months, but the survival dif- ference was not significant statistically. The side effects were acceptable. There were no episodes of any life threatening toxicities.
  • 3,260 View
  • 15 Download
Close layer
Prognostic Factors in Node - Negative Breast Cancer
Kyung Hee Lee, Hyun Cheol Chung, Jae Yong Cho, Sun Young Rha, Joong Bae Ahn, Chong In Lee, Nae Choon Yoo, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim, Kyung Sik Lee, Kyl Beom Lee, Ho Yeong Lim, Jin Hy
J Korean Cancer Assoc. 1995;27(2):265-275.
AbstractAbstract PDF
Breast cancer is the third most common malignant neoplasm in Korean women. The effect of postoperative adjuvant systemic therapy in the treatment of primary breast cancer with pathologic involvement of the axillary lymph nodes has been well established. But, 20 30% of node-negative breast cancer patients will develop recurrent disease and risk death within 10 years after initial local therapy without adjuvant treatment. Therfore, it is reasonable to identify those node-negative breast cancer patients at significant risk for recurrence and who could be treated with adjuvant therapies. A clinical study was perofrmed in 184 cases of primary node-negative breast cancers from January 198l to December 1991 to study the natural course of the diaease and to find-out the prognostic factors. The following results were obtained; l) During 73 monthe(9-143) of follow-up duration, 5-year and 10-year relapse free survival rates were 88%, 77% respectively, and overall survival rates were 89%, 88%, respectively. 10 year recurrence rate was 19%. 2) Median disease-free and survival durations were 80 month, 17 months, respectively, in tumor size<2 cm group and 68.5 months, 62 months respectively in tumor size 2-5 cm group. 3) Median disease-free and overall survival durations were 73 months, 61 months, respectively, in premenopause patients and 74 months, 73 months in postmenopause patients. 4) No differences were found in disease-free and survival duration based on types of operation. 5) With adjuvant treatment, there was a decreasing tendency of systemic relapse. In conclusion, continuous relapse was found in node-negative breast cancer even after 5 years of operation. Even if decreasing tendency of systemic relapse was induced with adjuvant treatment, no clinically useful prognostic factors were found from surgical and pathologic factors until now. Further study of biological factors in node-negative breast cancer is warrented.
  • 3,309 View
  • 14 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP